[{"text": "Akebia announces \u2018multiple positive business updates\u2019 TipRanks Tue, Jan 14, 2025, 4:28 PM 1 min read In This Article: AKBA -5.36% https://www.tipranks.com/news/the-fly/mind-medicine-doses-first-patient-in-panorama-study Akebia ( AKBA ) Therapeutics announced multiple positive business updates. As of January, Vafseo tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease on dialysis for at least three months, and shipment of product to dialysis centers has commenced. In addition, Akebia recently signed a Vafseo commercial supply agreement with a leading dialysis organization. Akebia now has contracts in place with dialysis organizations caring for nearly 100% of dialysis patients in the U.S. As previously announced, Vafseo qualifies for the Transitional Drug Add-On Payment Adjustment reimbursement as directed by the Centers for Medicare & Medicaid Services, and CMS has published billing guidance and reimbursement rates. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today\u2019s best-performing stocks on TipRanks >> Read More on AKBA: Akebia: U.S. Renal Care enrolls first patient in its VOICE collaborative trial Biotech Alert: Searches spiking for these stocks today View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AKBA", "date": "2025-01-14T16:28:06", "sentiment": {"score": 0.12660655286163092, "confidence": 0.1373562067747116, "probabilities": {"positive": 0.1373562067747116, "negative": 0.010749653913080692, "neutral": 0.8518940806388855}}, "embedding": [-0.12911556661128998, -0.18316061794757843, -0.057661667466163635, -0.06335984170436859, -0.18292906880378723, -0.002137361327186227, 0.08975955098867416, 0.1276743859052658, 0.0637822225689888, 0.018194442614912987, -0.08133005350828171, 0.14023499190807343, -0.13118185102939606, -0.05759619548916817, -0.07212886214256287, -0.1112288162112236, 0.16580961644649506, -0.050512831658124924, -0.10971524566411972, 0.06617503613233566, -0.0404265895485878, -0.070245660841465, 0.037838369607925415, -0.11127566546201706, 0.1091400682926178, 0.010350181721150875, -0.1083860695362091, -0.08811807632446289, -0.08998039364814758, -0.16420117020606995, -0.00021042877051513642, 0.11032283306121826, 0.08542086184024811, -0.1091507226228714, -0.05176611989736557, 0.14066821336746216, -0.22663335502147675, 0.10077376663684845, -0.06459808349609375, -0.020525377243757248, 0.12341423332691193, -0.14597134292125702, -0.12551626563072205, -0.03695524111390114, -0.07712490856647491, -0.1668604612350464, -0.11308109760284424, -0.03778597339987755, 0.19405436515808105, 0.21285516023635864, -0.3027782142162323, -0.19929449260234833, 0.07292139530181885, 0.12882380187511444, -0.1320221722126007, -0.07494445890188217, -0.07835482805967331, 0.010459152050316334, 0.00030432880157604814, -0.05186012014746666, 0.07259427011013031, 0.03343409672379494, 0.10474716126918793, -0.01676611416041851, 0.06012223660945892, 0.09047815948724747, 0.07464458048343658, -0.0448891744017601, 0.029125569388270378, -0.19900228083133698, 0.09237662702798843, -0.03476381674408913, 0.0024097480345517397, 0.12739470601081848, -0.12749961018562317, 0.12587495148181915, 0.07961522787809372, 0.037262383848428726, 0.20407690107822418, -0.06431577354669571, 0.044909898191690445, 0.11935051530599594, 0.048932597041130066, 0.03287490829825401, -0.04092036187648773, -0.009683128446340561, -0.016310229897499084, 0.07610239833593369, 0.11894883960485458, -0.02373003028333187, 0.14610910415649414, 0.13843221962451935, 0.07981729507446289, -0.10592735558748245, 0.045505303889513016, -0.09799843281507492, -0.17954955995082855, -0.12213079631328583, -0.0714842677116394, 0.044232167303562164, 0.004531541373580694, 0.09309559315443039, 0.04487208276987076, -0.07829167693853378, 0.0035119906533509493, -0.1123737245798111, 0.004920629318803549, -0.06747045367956161, 0.03984517604112625, 0.018867265433073044, -0.09826520085334778, 0.09561919420957565, 0.08892039209604263, -0.07292022556066513, -0.06833631545305252, 0.10823087394237518, -0.03382152318954468, -0.016604438424110413, 0.1996568739414215, 0.05961167439818382, 0.03841376304626465, 0.020610403269529343, -0.05467678979039192, -0.1613340675830841, 0.08839645981788635, 0.11650232970714569, -0.15213695168495178, 1.0980023102014268e-32, 0.011721864342689514, 0.033860400319099426, 0.15577968955039978, 0.006366872228682041, -0.01697341352701187, 0.06387508660554886, -0.05885282903909683, -0.08842906355857849, -0.14801008999347687, -0.155605748295784, -0.27900853753089905, 0.039693791419267654, -0.06599479168653488, 0.11335636675357819, -0.051520299166440964, -0.09800197184085846, -0.026260733604431152, 0.05140677094459534, 0.18118764460086823, 0.08038643002510071, 0.12467264384031296, -0.09286338835954666, -0.03699704259634018, 0.0065765236504375935, 0.0007016737945377827, 0.009289562702178955, -0.0927010178565979, 0.035956863313913345, 0.018012624233961105, 0.06860390305519104, -0.02051077038049698, 0.06394173204898834, -0.08220211416482925, -0.20216643810272217, -0.18497808277606964, -0.09618588536977768, -0.11535187065601349, -0.08381672948598862, -0.10887029021978378, -0.040584661066532135, -0.10648256540298462, 0.17885324358940125, -0.0628075897693634, 0.019521566107869148, 0.06497222185134888, -0.04443732276558876, -0.16818055510520935, -0.0013466922100633383, 0.08669861406087875, 0.02803405001759529, -0.17033028602600098, -0.04657057300209999, 0.04349403455853462, -0.00728066498413682, -0.015100255608558655, 0.013745768927037716, -0.066489078104496, -0.05050976201891899, -0.0055975099094212055, 0.04976346343755722, 0.10562258213758469, 0.06362615525722504, -0.004875353071838617, 0.03840770572423935, -0.09117836505174637, 0.09375874698162079, 0.002354849362745881, -0.02339118905365467, -0.07432577759027481, 0.033294688910245895, -0.009952454827725887, 0.06033247709274292, 0.08795559406280518, 0.029272649437189102, -0.10315012186765671, -0.1049557775259018, -0.05900678411126137, -0.06897704303264618, -0.006425862200558186, -0.04969251900911331, 0.06388017535209656, -0.10495062917470932, 0.03198201209306717, 0.20414623618125916, 0.11807253211736679, 0.03575178235769272, 0.13618962466716766, -0.048256468027830124, -0.1307789385318756, -0.15224124491214752, -0.043298330157995224, 0.12232711911201477, -0.10894101858139038, 0.18009383976459503, -0.01396858599036932, -1.1179447187999207e-32, 0.05782429873943329, -0.001945116207934916, 0.02067955769598484, 0.04195012152194977, 0.06373794376850128, 0.057162828743457794, 0.14813882112503052, -0.0010977542260661721, 0.07482268661260605, 0.07489315420389175, 0.028431223705410957, 0.08667921274900436, 0.008721556514501572, -0.02591194584965706, -0.0587964728474617, 0.009108645841479301, 0.027931587770581245, -0.0920957699418068, -0.0008642770699225366, -0.1071082279086113, -0.028983358293771744, 0.10295704752206802, -0.11653493344783783, 0.14727726578712463, 0.04923843592405319, -0.016667412593960762, 0.038464177399873734, 0.11443185806274414, -0.1891879141330719, -0.026499778032302856, 0.03796476870775223, 0.09247185289859772, -0.18745283782482147, 0.03938714414834976, -0.095412977039814, 0.009854618459939957, 0.1427610218524933, -0.18749317526817322, 0.0328044518828392, -0.0042189606465399265, 0.18557842075824738, 0.008841211907565594, 0.024626202881336212, -0.005389453377574682, -0.029795873910188675, -0.01114638615399599, 0.03178044781088829, 0.022625159472227097, 0.04930151253938675, -0.13113659620285034, -0.05177992209792137, 0.04736867547035217, 0.05053797736763954, 0.16710059344768524, -0.01257153507322073, 0.05461251735687256, 0.051834043115377426, 0.02095790021121502, -0.17068804800510406, -0.008353677578270435, -0.05655958876013756, 0.05530126765370369, 0.10764938592910767, -0.056203693151474, 0.038893651217222214, 0.06577445566654205, 0.2380913645029068, 0.093824103474617, 0.02786504104733467, -0.093433678150177, 0.027233345434069633, -0.12158595025539398, 0.1149144247174263, -0.10905656963586807, 0.0019424936035647988, 0.17446333169937134, 0.060019154101610184, -0.04896146431565285, -0.0362979918718338, -0.13131646811962128, 0.03613423556089401, -0.17714214324951172, -0.013146226294338703, 0.0422494038939476, -0.006357398349791765, 0.1292460411787033, 0.13870497047901154, -0.10605092346668243, 0.003471619449555874, 0.10874597728252411, -0.2114160656929016, -0.2078782320022583, -0.13740897178649902, 0.1320430487394333, 0.06984928995370865, -1.0073529210785637e-07, 0.11513934284448624, -0.025832323357462883, -0.005756775848567486, -0.00818614847958088, 0.07994796335697174, -0.07336658984422684, -0.03543274849653244, 0.12783615291118622, -0.053333766758441925, 0.11976876109838486, 0.040362462401390076, 0.15056025981903076, -0.0534961074590683, 0.08636218309402466, 0.10443013906478882, 0.10174984484910965, -0.008104423061013222, 0.1349562704563141, -0.11115819960832596, -0.04350452125072479, -0.06233381852507591, 0.007751221768558025, 0.08244578540325165, -0.04227235168218613, 0.05156806856393814, -0.04001295194029808, 0.05313333868980408, -0.0837116464972496, 0.07316885888576508, -0.01835586130619049, -0.05122747644782066, 0.03702116385102272, 0.20684818923473358, -0.05785714462399483, -0.047472164034843445, 0.026102950796484947, -0.00695100286975503, 0.047809675335884094, 0.008758492767810822, 0.04770909249782562, -0.04641279578208923, -0.11584257334470749, -0.056842777878046036, -0.04770867899060249, 0.06928657740354538, 0.05917807295918465, -0.07937279343605042, 0.019974542781710625, 0.03605383634567261, -0.15499991178512573, 0.03915157541632652, 0.10067380964756012, 0.057417694479227066, 0.028105666860938072, -0.05793176218867302, 0.15919086337089539, -0.11704441905021667, -0.011650120839476585, 0.06068476662039757, 0.0292255450040102, 0.14451107382774353, -0.18697448074817657, -0.021172618493437767, 0.019469114020466805], "changes": {"1wk": 9.523806820651009}}, {"text": "Akebia Therapeutics Announces Multiple Positive Business Updates PR Newswire Mon, Jan 13, 2025, 4:00 PM 11 min read In This Article: AKBA -5.36% New Commercial Supply Contracts for Vafseo\u00ae (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Vafseo tablets now shipping in the U.S. Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo label to include treatment of late-stage non-dialysis CKD patients Company to discuss business updates at 43 rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. , Jan. 13, 2025 /PRNewswire/ -- Akebia Therapeutics \u00ae , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced multiple positive business updates. As of January, Vafseo\u00ae (vadadustat) tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease (CKD) on dialysis for at least three months, and shipment of product to dialysis centers has commenced. In addition, Akebia recently signed a Vafseo commercial supply agreement with a leading dialysis organization. Akebia now has contracts in place with dialysis organizations caring for nearly 100% of dialysis patients in the U.S. As previously announced, Vafseo qualifies for the Transitional Drug Add-On Payment Adjustment (TDAPA) reimbursement as directed by the Centers for Medicare & Medicaid Services (CMS), and CMS has published billing guidance and reimbursement rates. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.) Akebia also announced its plans to begin a Phase 3 trial for the use of vadadustat in treating anemia in late-stage CKD patients who are not on dialysis. Akebia received feedback from the U.S. Food and Drug Administration (FDA) on its protocol submission for a label expansion study and is incorporating feedback as appropriate. Akebia expects to begin the trial in mid-2025. \"We believe Akebia is entering a transformational year with the U.S. market availability of Vafseo, which we believe could become a new standard of care for patients with CKD,\" said John P. Butler , Chief Executive Officer of Akebia. \"During 2025 our commercial organization will remain focused on executing the U.S. launch of Vafseo, while our development team pursues label expansion of Vafseo into the non-dialysis population, which represents a potential multiple billion-dollar market opportunity in the U.S. We believe our commercial products and pipeline have the potential to generate significant shareholder value as Akebia strengthens its leadership position in the treatment of kidney disease and the hypoxia-inducible factor (HIF) space.\" Vafseo Commercial Update: Vafseo began shipping to dialysis centers and authorized distributors on January 9, 2025 . Akebia has secured broad access for Vafseo as the company has now entered into commercial supply agreements with dialysis organizations treating nearly 100% of patients on dialysis in the U.S., including recently signing agreements with a leading dialysis organization and a mid-size dialysis provider. Akebia market research suggests 99% of nephrologists would consider prescribing Vafseo to certain eligible patients, with 75% intending to do so by 6 months after product availability. In December 2024 , Akebia announced that U.S. Renal Care enrolled the first patients in the VOICE collaborative clinical trial of Vafseo. U.S. Renal Care has now enrolled more than 650 patients in the trial. Story Continues Planned Phase 3 Trial of Vadadustat in U.S. Non-Dialysis CKD Patients: In March 2024 , the FDA approved Vafseo for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. The FDA acknowledged an unmet need for safer and orally available therapies to treat anemia due to CKD in certain non-dialysis patients. Akebia has since engaged with the FDA on potentially expanding vadadustat treatment to this patient population and has received feedback on a protocol submitted for a Phase 3 cardiovascular outcome study of approximately 1,500 U.S. subjects with late-stage CKD anemia not on dialysis, which is expected to begin in mid-2025. Akebia plans to request a Type C meeting with the FDA to continue to discuss the statistical analysis plan and regulatory path. Akebia expects its existing cash resources and cash from operations will be sufficient to fund its current operating plan, including the U.S. Vafseo launch and planned pipeline advancement, for at least two years. Presentation at 43 rd J.P. Morgan Healthcare Conference John Butler , Chief Executive Officer, will present\u00a0on\u00a0Thursday, January 16 th , 2025 at\u00a07:30 a.m. PST. A webcast of the presentation can be accessed through the \"Investors\" section of Akebia's website for 30 days following the conference. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release. About Vafseo\u00ae (vadadustat) tablets Vafseo\u00ae (vadadustat) tablets is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin, increasing hemoglobin and red blood cell production to manage anemia. Vafseo is approved for use in 37 countries. INDICATION VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being. VAFSEO is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. In patients with anemia due to\u00a0CKD not on dialysis. IMPORTANT SAFETY INFORMATION about VAFSEO (vadadustat) tablets WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS. VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE). Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels. No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks. Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions. CONTRAINDICATIONS Known hypersensitivity to VAFSEO or any of its components Uncontrolled hypertension WARNINGS AND PRECAUTIONS Increased Risk of Death, Myocardial Infarction (MI), Stroke, Venous Thromboembolism, and Thrombosis of Vascular Access A rise in hemoglobin (Hb) levels greater than 1 g/dL over 2 weeks can increase these risks. Avoid in patients with a history of MI, cerebrovascular event, or acute coronary syndrome within the 3 months prior to starting VAFSEO. Targeting a Hb level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events. Use the lowest effective dose to reduce the need for red blood cell (RBC) transfusions. Adhere to dosing and Hb monitoring recommendations to avoid excessive erythropoiesis. Hepatotoxicity Hepatocellular injury attributed to VAFSEO was reported in less than 1% of patients, including one severe case with jaundice. Elevated serum ALT, AST, and bilirubin levels were observed in 1.8%, 1.8%, and 0.3% of CKD patients treated with VAFSEO, respectively. Measure ALT, AST, and bilirubin before treatment and monthly for the first 6 months, then as clinically indicated. Discontinue VAFSEO if ALT or AST is persistently elevated or accompanied by elevated bilirubin. Not recommended in patients with cirrhosis or active, acute liver disease. Hypertension Worsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. Serious worsening of hypertension was reported in 2.7% of VAFSEO and 3% of darbepoetin alfa patients. Cases of hypertensive crisis, including hypertensive encephalopathy and seizures, have also been reported in patients receiving VAFSEO. Monitor blood pressure. Adjust anti-hypertensive therapy as needed. Seizures Seizures occurred in 1.6% of VAFSEO and 1.6% of darbepoetin alfa patients. Monitor for new-onset seizures, premonitory symptoms, or change in seizure frequency. Gastrointestinal (GI) Erosion Gastric or esophageal erosions occurred in 6.4% of VAFSEO and 5.3% of darbepoetin alfa patients. Serious GI erosions, including GI bleeding and the need for RBC transfusions, were reported in 3.4% of VAFSEO and 3.3% of darbepoetin alfa patients. Consider this risk in patients at increased risk of GI erosion. Advise patients about signs of erosions and GI bleeding and urge them to seek prompt medical care if present. Serious Adverse Reactions in Patients with Anemia Due to CKD and Not on Dialysis The safety of VAFSEO has not been established for the treatment of anemia due to CKD in adults not on dialysis and its use is not recommended in this setting. In large clinical trials in adults with anemia of CKD who were not on dialysis, an increased risk of mortality, stroke, MI, serious acute kidney injury, serious hepatic injury, and serious GI erosions was observed in patients treated with VAFSEO compared to darbepoetin alfa . Malignancy VAFSEO has not been studied and is not recommended in patients with active malignancies. Malignancies were observed in 2.2% of VAFSEO and 3.0% of darbepoetin alfa patients. No evidence of increased carcinogenicity was observed in animal studies. ADVERSE REACTIONS The most common adverse reactions (occurring at \u2265 10%) were hypertension and diarrhea. DRUG INTERACTIONS Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron. Non-iron-containing phosphate binders : Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders. BCRP substrates : Monitor for signs of substrate adverse reactions and consider dose reduction. Statins : Monitor for statin-related adverse reactions. Limit the daily dose of simvastatin to 20 mg and rosuvastatin to 5 mg. USE IN SPECIFIC POPULATIONS Pregnancy: May cause fetal harm. Lactation: Breastfeeding not recommended until two days after the final dose. Hepatic Impairment : Not recommended in patients with cirrhosis or active, acute liver disease. Please note that this information is not comprehensive. Please click here for the Full Prescribing Information, including BOXED WARNING and Medication Guide. Forward-Looking Statements Statements in this press release regarding Akebia Therapeutics, Inc.'s (\"Akebia's\") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to, statements regarding: Akebia's plans with respect to its U.S. commercial launch of Vafseo, including Akebia's statements regarding commercial supply contract coverage for Vafseo with dialysis organizations and Akebia's ability to make Vafseo available to nearly 100% of patients on dialysis in the U.S.; Akebia's plans and expectations with respect to potential Vafseo label expansion to treat anemia in late-stage CKD patients who are not on dialysis, including Akebia's expectations as to the timing of a Phase 3 trial, Akebia's statements regarding feedback from the FDA on its protocol submission for a label expansion study and Akebia's plans to request a Type C meeting with the FDA to discuss the statistical plan and regulatory path; Akebia's belief that it is entering a transformational year with U.S. market availability of Vafseo, and Akebia's belief that Vafseo could become a new standard of care for patients with CKD; Akebia's expectations regarding label expansion of Vafseo into the non-dialysis population, including a potential multiple billion-dollar market opportunity in the U.S.; Akebia's belief that its commercial products and pipeline have the potential to generate significant shareholder value as Akebia strengthens its leadership position in the treatment of kidney disease and the HIF space; Akebia's expectations regarding the demand for Vafseo from prescribers; and Akebia's expectations that its existing cash resources and cash from operations will be sufficient to fund its current operating plan, including the U.S. Vafseo launch and planned pipeline advancement, for at least two years. The terms \"intend,\" \"believe,\" \"plan,\" \"goal,\" \"potential,\" \"anticipate, \"estimate,\" \"expect,\" \"future,\" \"will,\" \"continue,\" derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to, risks associated with: the commercial availability of Vafseo; the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to, Auryxia\u00ae and Vafseo, including estimates regarding the potential market opportunity; the competitive landscape for Auryxia and Vafseo, including potential generic entrants; the ability of Akebia to attract and retain qualified personnel; Akebia's ability to implement cost avoidance measures and reduce operating expenses; decisions made by health authorities, such as the FDA, with respect to regulatory filings and other interactions; the potential therapeutic benefits, safety profile, and effectiveness of Vafseo; the results of preclinical and clinical research; manufacturing, supply chain and quality matters and any recalls, write-downs, impairments or other related consequences or potential consequences; and early termination of any of Akebia's collaborations. Other risks and uncertainties include those identified under the heading \"Risk Factors\" in Akebia's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 , and other filings that Akebia may make with the U.S. Securities and Exchange Commission in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and, except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release. Akebia Therapeutics\u00ae, Auryxia and Vafseo\u00ae are registered trademarks of Akebia Therapeutics, Inc. and its affiliates. Akebia Therapeutics Contact Mercedes Carrasco mcarrasco@akebia.com Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-multiple-positive-business-updates-302348919.html SOURCE Akebia Therapeutics, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AKBA", "date": "2025-01-13T16:00:00", "sentiment": {"score": 0.2580149946734309, "confidence": 0.26687315106391907, "probabilities": {"positive": 0.26687315106391907, "negative": 0.008858156390488148, "neutral": 0.7242687344551086}}, "embedding": [-0.11237414926290512, -0.1187707781791687, -0.05885762721300125, -0.14472578465938568, -0.19396038353443146, -0.014531693421304226, -0.03216587007045746, 0.12752479314804077, 0.1413135975599289, 0.02172255329787731, -0.03727741166949272, 0.07929155975580215, -0.12130631506443024, -0.05764805153012276, 0.05569733306765556, -0.1049216091632843, 0.1977994740009308, 0.05886971950531006, -0.11619946360588074, 0.08357129245996475, 0.09442706406116486, 0.09187053143978119, -0.004072071053087711, -0.09925095736980438, 0.058771125972270966, 0.0002568373456597328, -0.1439729928970337, -0.09132315218448639, -0.050142932683229446, -0.07827793061733246, 0.039491381496191025, 0.0827542096376419, 0.026762699708342552, -0.11915101110935211, 0.043085142970085144, 0.07754682004451752, -0.2762583792209625, 0.07087180018424988, -0.20922419428825378, -0.07385838031768799, 0.05509655177593231, -0.09802214801311493, -0.13863947987556458, -0.0073677655309438705, -0.10322879254817963, -0.11893682926893234, -0.09205453097820282, -0.014512193389236927, 0.06984856724739075, 0.18164819478988647, -0.15461942553520203, -0.16169533133506775, 0.08155176788568497, 0.12987196445465088, -0.14926426112651825, -0.1116943508386612, -0.058947496116161346, 0.015817373991012573, -0.015138020738959312, -0.019727960228919983, -0.05754382535815239, 0.029405485838651657, -0.0058118607848882675, -0.04299147427082062, 0.0822247713804245, 0.12612871825695038, 0.13375791907310486, -0.14867524802684784, -0.009878851473331451, -0.1725490242242813, 0.020105574280023575, -0.0031462248880416155, 0.0812593325972557, 0.16025972366333008, -0.0480077862739563, 0.15115627646446228, 0.07417505979537964, 0.02678600512444973, 0.20574107766151428, -0.13526727259159088, 0.08806228637695312, 0.18780967593193054, 0.05855991318821907, 0.002846021903678775, -0.006711648777127266, 0.024326752871274948, -0.042719073593616486, 0.10301662981510162, 0.059045515954494476, -0.03975959122180939, 0.17981469631195068, 0.12460392713546753, 0.10104862600564957, -0.060318753123283386, -0.028726335614919662, -0.11048740893602371, -0.08382865786552429, -0.031774602830410004, -0.0017563020810484886, 0.03016478382050991, -0.045957401394844055, 0.06260588765144348, -0.0359671525657177, -0.09245835244655609, 0.009687813930213451, -0.06710536777973175, -0.021372713148593903, -0.058494023978710175, 0.011728554964065552, 0.05767554044723511, -0.07465872168540955, 0.016560908406972885, 0.09656702727079391, -0.06219641491770744, -0.03092973306775093, 0.0774204358458519, 0.0026221368461847305, -0.012362727895379066, 0.1851149946451187, -0.0642489492893219, -0.0058677708730101585, -0.02759404107928276, -0.018109798431396484, -0.11057598888874054, 0.035831183195114136, 0.10628741979598999, -0.03756830096244812, 1.1997665459252415e-32, -0.006562686059623957, -0.05433501675724983, 0.13612684607505798, -0.0007153861224651337, 0.02811722457408905, 0.06541991233825684, -0.07871519774198532, -0.014219962060451508, -0.06396561861038208, -0.1695670634508133, -0.17914187908172607, -0.011290288530290127, -0.06840229034423828, 0.14019283652305603, -0.08216241002082825, -0.08036944270133972, -0.03989129886031151, 0.021821923553943634, 0.15743820369243622, 0.12970486283302307, 0.12046273052692413, -0.02271967940032482, 0.04166492447257042, 0.10471026599407196, -0.052317507565021515, -0.001618985435925424, -0.04338270053267479, 0.10443848371505737, -0.055320750921964645, 0.05213850736618042, -0.07233426719903946, 0.020581653341650963, -0.0031700790859758854, -0.19137324392795563, -0.22787189483642578, -0.06778007745742798, -0.09510233998298645, -0.09768007695674896, -0.10135726630687714, -0.03317415714263916, -0.07236938178539276, 0.1007576435804367, -0.10556261241436005, 0.004586459137499332, 0.13538268208503723, -0.11360608041286469, -0.09337950497865677, 0.005579381249845028, 0.00012576859444379807, 0.05238168314099312, -0.12474207580089569, -0.015677694231271744, 0.02657501772046089, -0.04733739048242569, -0.02436450682580471, -0.007414510473608971, -0.0762859582901001, -0.03700706735253334, 0.07672624289989471, 0.10321132838726044, 0.048771124333143234, 0.0677785873413086, 0.04186449572443962, 0.11536020040512085, -0.08442271500825882, 0.08559128642082214, -0.03011159971356392, -0.08971971273422241, -0.028810199350118637, -0.09043806791305542, -0.03936408460140228, 0.049189649522304535, 0.08342684060335159, 0.015795480459928513, -0.025153405964374542, -0.1696341633796692, 0.03271275386214256, 0.04502492398023605, -0.037787120789289474, -0.07237476855516434, 0.024647165089845657, -0.05259564891457558, -0.042065102607011795, 0.17928430438041687, 0.06510686874389648, 0.004164820536971092, 0.04442242905497551, -0.0007727873744443059, -0.19609814882278442, -0.1647026091814041, 0.0421840064227581, 0.026983968913555145, -0.071518674492836, 0.23093301057815552, 0.09193649142980576, -1.2651249134517238e-32, 0.08329245448112488, 0.009314286522567272, -0.009734916500747204, -0.025662656873464584, 0.047845326364040375, 0.0937303900718689, 0.10552487522363663, -0.032252147793769836, 0.07630041986703873, -0.036910176277160645, 0.028531091287732124, 0.06617540121078491, 0.004102633334696293, -0.05852583795785904, -0.09124337881803513, 0.04751795157790184, 0.038934677839279175, -0.1124134212732315, -0.033075761049985886, 0.022190555930137634, -0.0017418167553842068, 0.12551766633987427, -0.06730146706104279, 0.0727328360080719, 0.05897200107574463, -0.09582030028104782, 0.052691731601953506, 0.1057133600115776, -0.08070513606071472, -0.04452890902757645, 0.05496783182024956, 0.06483644992113113, -0.21320299804210663, 0.00283926073461771, -0.03083239123225212, -0.10756571590900421, 0.152020663022995, -0.14075109362602234, 0.04643531143665314, -0.02008531428873539, 0.12639620900154114, 0.03308599814772606, -0.05645053833723068, 0.014305326156318188, -0.044400885701179504, 0.008073408156633377, 0.06664498895406723, -0.14840246737003326, 0.05382011830806732, -0.11722257733345032, 0.004125883337110281, 0.026608336716890335, 0.05602598935365677, 0.1465539038181305, -0.0008466881699860096, 0.029721016064286232, 0.0642348974943161, 0.0052101826295256615, -0.12251841276884079, 0.06916666030883789, -0.05660630017518997, 0.04793800413608551, 0.1393863558769226, -0.09213981032371521, 0.1087828204035759, 0.08685926347970963, 0.19801682233810425, 0.05900769308209419, 0.10705007612705231, -0.08510590344667435, -0.038289763033390045, -0.07988087832927704, 0.04378708451986313, -0.06418534368276596, 0.042304422706365585, 0.06479930877685547, 0.08022529631853104, -0.09744259715080261, -0.08544841408729553, -0.10096425563097, 0.03277064859867096, -0.1838548183441162, -0.04669759422540665, 0.01749703846871853, 0.007738868705928326, 0.03992370516061783, 0.09135335683822632, -0.06765661388635635, 0.03200183063745499, 0.20885521173477173, -0.13787376880645752, -0.12481658905744553, -0.08239912986755371, 0.13873180747032166, 0.13749167323112488, -1.0134660044514021e-07, 0.14922824501991272, 0.006714998744428158, -0.007372912019491196, -0.019466444849967957, 0.002613854594528675, -0.07654620707035065, 0.018297530710697174, 0.07233476638793945, -0.08945436030626297, 0.09824658930301666, 0.06657417118549347, 0.16920238733291626, -0.06472226232290268, 0.06711100041866302, 0.05953396484255791, 0.1420828402042389, 0.003602541983127594, 0.10118002444505692, -0.08873216807842255, 0.0418558269739151, -0.16411027312278748, -0.04917413741350174, 0.009638975374400616, -0.0646250993013382, 0.06016832962632179, -0.08233898878097534, 0.0705561488866806, -0.07947862148284912, 0.05816212669014931, -0.03475288301706314, -0.060675978660583496, 0.020946146920323372, 0.10241071879863739, -0.05141979083418846, -0.10015440732240677, -0.07893955707550049, 0.006370624527335167, 0.02354339510202408, 0.03970449045300484, 0.043097611516714096, -0.015092223882675171, -0.11575746536254883, -0.03843975439667702, -0.03253079950809479, 0.07188192009925842, 0.09570653736591339, -0.138731449842453, 0.020777639001607895, -0.057490237057209015, -0.05669364705681801, -0.01192403119057417, 0.13473959267139435, 0.027037467807531357, 0.0003339005634188652, -0.0593176931142807, 0.12950506806373596, -0.06561867892742157, -0.05331123247742653, 0.146076500415802, -0.010573500767350197, 0.15499405562877655, -0.08774314820766449, 0.05097677558660507, -0.055214934051036835], "changes": {"1wk": 10.695183313606426}}, {"text": "New Strong Sell Stocks for January 3rd Zacks Equity Research Fri, Jan 3, 2025, 12:52 PM 1 min read In This Article: AKBA -5.36% KOF -1.54% Here are three stocks added to the Zacks Rank #24 (Strong Sell) List today: Akebia Therapeutics, Inc. AKBA is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 26.3% downward over the last 60 days. Coca-Cola FEMSA, S.A.B. de C.V. KOF is a franchise bottling company. The Zacks Consensus Estimate for its current year earnings has been revised 7.9% downward over the last 60 days. Guess?, Inc. GES is an apparel and accessories company. The Zacks Consensus Estimate for its current year earnings has been revised 27% downward over the last 60 days. View the entire Zacks Rank #5 List. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Guess?, Inc. (GES) : Free Stock Analysis Report Coca Cola Femsa S.A.B. de C.V. (KOF) : Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AKBA", "date": "2025-01-03T12:52:00", "sentiment": {"score": -0.31813626922667027, "confidence": 0.3446780741214752, "probabilities": {"positive": 0.026541804894804955, "negative": 0.3446780741214752, "neutral": 0.6287800669670105}}, "embedding": [-0.2385852038860321, -0.15945285558700562, -0.1215355396270752, 0.12492358684539795, 0.04099973663687706, 0.03554053604602814, 0.021879954263567924, 0.11932206898927689, -0.02960139326751232, 0.03377870097756386, -0.07670827955007553, 0.161449134349823, -0.06096218526363373, -0.04859967529773712, 0.012958304025232792, -0.030413083732128143, 0.13174746930599213, -0.021067962050437927, -0.1882682740688324, -0.02549630030989647, -0.10469185560941696, -0.13932162523269653, 0.15993057191371918, -0.004036028869450092, 0.03859167918562889, 0.06148110330104828, -0.05389941856265068, -0.015525486320257187, -0.1110520288348198, -0.1941986382007599, -0.10067626088857651, 0.06455991417169571, 0.16604235768318176, -0.07715871930122375, -0.04954582080245018, 0.013432500883936882, -0.06553047150373459, 0.006952284835278988, 0.19430893659591675, 0.005977367516607046, 0.03197424113750458, 0.038529425859451294, -0.07796072214841843, -0.08435449749231339, -0.14170679450035095, -0.11213583499193192, -0.07229666411876678, 0.007662064395844936, 0.10786105692386627, 0.06220836192369461, -0.2684153616428375, -0.1233016848564148, 0.11084447056055069, -0.014878443442285061, -0.09869200736284256, -0.0006357666570693254, -0.19475391507148743, -0.20970074832439423, 0.09967787563800812, 0.06669572740793228, 0.18356941640377045, 0.006074684672057629, 0.09855786710977554, 0.09871139377355576, 0.050018489360809326, -0.02612842433154583, 0.023852957412600517, 0.04616878926753998, -0.044170282781124115, -0.023555051535367966, 0.08081305772066116, -0.095579132437706, -0.06629851460456848, 0.14990679919719696, -0.10275469720363617, 0.06873954832553864, 0.13541769981384277, 0.09745490550994873, 0.12285341322422028, -0.057223424315452576, 0.0033964812755584717, -0.006552975624799728, 0.01574540138244629, -0.02834245376288891, -0.048650410026311874, 0.011075901798903942, 0.021927768364548683, 0.026384493336081505, 0.05318189039826393, 0.06522039324045181, 0.12977267801761627, 0.03220339119434357, 0.12774084508419037, -0.05828172713518143, -0.08663210272789001, -0.04648236557841301, -0.12113584578037262, 0.08064840734004974, -0.08047101646661758, 0.056657176464796066, 0.04754830524325371, 0.22884662449359894, 0.0009673370514065027, -0.03849609196186066, 0.016633279621601105, -0.2086639702320099, 0.018497418612241745, 0.039168938994407654, -0.03138279914855957, 0.19649632275104523, -0.07261688262224197, 0.10176367312669754, -0.03269278258085251, -0.026331784203648567, -0.079531729221344, -0.008997097611427307, -0.017562391236424446, 0.06552799046039581, 0.1544923633337021, 0.07941480726003647, 0.09262023121118546, 0.17253677546977997, 0.02096138522028923, -0.07932854443788528, -0.007561349775642157, 0.09953033924102783, -0.17518679797649384, 9.770199908044154e-33, -0.027951763942837715, 0.1082763522863388, 0.15982218086719513, -0.033866919577121735, -0.0767638310790062, -0.06230204179883003, -0.07098891586065292, -0.04254238307476044, -0.08653539419174194, 0.00164549401961267, -0.2211686372756958, 0.10984340310096741, -0.058312371373176575, -0.03247952088713646, -0.034722987562417984, -0.03678227216005325, -0.030057338997721672, -0.086356520652771, 0.07985420525074005, -0.07635172456502914, 0.11089121550321579, -0.033583249896764755, -0.006087726913392544, 0.010510045103728771, 0.08820530027151108, -0.05943746119737625, -0.04909854754805565, 0.055923666805028915, -0.1765654981136322, 0.10492268949747086, -0.026723751798272133, -0.00047501278459094465, -0.07323278486728668, -0.0177393089979887, -0.16721133887767792, -0.17325133085250854, -0.09531734138727188, -0.03158784657716751, 0.04522803798317909, -0.05273735895752907, -0.09307318180799484, 0.11861563473939896, -0.1567065715789795, 0.026172326877713203, -0.04565012827515602, 0.14184942841529846, -0.1332654505968094, 0.073754221200943, 0.17016398906707764, 0.07726375758647919, -0.15143127739429474, -0.050826672464609146, -0.01191622018814087, 0.09880705922842026, -0.04908646643161774, 0.033270880579948425, -0.009917350485920906, -0.1297166496515274, 0.06217502802610397, 0.03887317329645157, 0.037552155554294586, 0.20210854709148407, 0.021443136036396027, -0.1001029834151268, -0.14307421445846558, 0.08528685569763184, -0.008836504071950912, 0.108671635389328, -0.08223956823348999, 0.05211644247174263, 0.0709337443113327, 0.08826036006212234, 0.14253000915050507, -0.059262774884700775, 0.0518808513879776, -0.06059325486421585, 0.047560714185237885, -0.01765984296798706, 0.0680888220667839, 0.07445118576288223, 0.14574077725410461, -0.020223913714289665, 0.07633476704359055, 0.08881472051143646, 0.04852255806326866, -0.041899245232343674, 0.02415565960109234, -0.005062195472419262, -0.05769529938697815, -0.043672773987054825, -0.013042491860687733, 0.007438610307872295, -0.05936136469244957, 0.08731280267238617, -0.04242078214883804, -9.64904243998887e-33, 0.13512417674064636, 0.015567908063530922, 0.06992650777101517, -0.006747244391590357, -0.0493413470685482, -0.054347358644008636, 0.0624484121799469, 0.11958063393831253, 0.007477595936506987, -0.02413197234272957, 0.11446337401866913, 0.09442165493965149, -0.0349416509270668, 0.024735840037465096, 0.01369552593678236, -0.03400589898228645, 0.07265834510326385, -0.08461213856935501, -0.011819425038993359, -0.11846235394477844, 0.050723109394311905, 0.11513067036867142, -0.1701783835887909, 0.130694180727005, 0.03382221981883049, 0.013345523737370968, -0.034354403614997864, 0.08375387638807297, -0.06644603610038757, 0.06445956975221634, 0.08317692577838898, 0.02159367874264717, -0.11117486655712128, 0.13539695739746094, -0.07821904867887497, -0.14353543519973755, 0.03209942951798439, -0.14115776121616364, 0.011742179282009602, -0.16061821579933167, 0.0809515118598938, 0.11708353459835052, -0.01925942674279213, -0.0015498603461310267, 0.08413389325141907, 0.03163853660225868, 0.04818429797887802, -0.0574648380279541, 0.19738487899303436, -0.010120905004441738, -0.047111500054597855, 0.010706747882068157, -0.12716640532016754, 0.13303142786026, -0.09506060928106308, 0.028890371322631836, 0.04454850032925606, -0.0037103043869137764, -0.24556954205036163, -0.0073926933109760284, 0.007038290612399578, 0.16822902858257294, 0.0475272461771965, 0.03710912540555, -0.021738510578870773, 0.05180464684963226, 0.06909008324146271, 0.11717725545167923, 0.031186627224087715, -0.19474683701992035, 0.023662971332669258, -0.08949023485183716, 0.050577953457832336, -0.11950347572565079, -0.10482041537761688, 0.23226062953472137, -0.07458585500717163, -0.06308732181787491, -0.05767473578453064, 0.037532418966293335, 0.10971545428037643, -0.04222748428583145, -0.07307340204715729, 0.13869531452655792, 0.006369531620293856, 0.151830792427063, 0.014602527022361755, -0.11779087036848068, 0.06419573724269867, 0.042324937880039215, -0.07445040345191956, -0.20647485554218292, -0.1450090855360031, 0.19839711487293243, 0.13672810792922974, -9.943054379846217e-08, 0.09720666706562042, -0.09036669880151749, -0.014506244100630283, -0.0038195126689970493, 0.14870217442512512, -0.007313752081245184, -0.1535457968711853, -0.050186026841402054, 0.10466077923774719, 0.06793341040611267, 0.09496820718050003, 0.09789850562810898, -0.24680131673812866, 0.128482848405838, -0.14267562329769135, -0.08093243092298508, -0.12104583531618118, 0.11757951974868774, 0.04137231782078743, -0.14594987034797668, -0.02089393138885498, 0.04306299611926079, 0.19414712488651276, -0.032470181584358215, 0.07835426181554794, -0.07595155388116837, -0.1387539952993393, -0.09461672604084015, 0.026661429554224014, 0.031961653381586075, -0.023505814373493195, 0.0033742652740329504, 0.06424346566200256, 0.06788814812898636, 0.05783308297395706, -0.06834162771701813, 0.00822169054299593, -0.040771931409835815, -0.0595177561044693, 0.0837165042757988, -0.018737969920039177, -0.13427679240703583, -0.11377362161874771, -0.008328578434884548, -0.0115962577983737, 0.0017190034268423915, -0.05842919275164604, 0.013578259386122227, 0.0691618025302887, -0.1744345724582672, 0.10105302929878235, -0.03561240807175636, 0.017863169312477112, 0.11748998612165451, -0.0045998673886060715, 0.10975076258182526, -0.2054687738418579, -0.01712895557284355, -0.07212651520967484, 0.0017353639705106616, 0.08897170424461365, -0.29352423548698425, -0.00868859514594078, 0.17727653682231903], "changes": {"1wk": -6.770833236320563, "1mo": 16.66666977107532}}, {"text": "Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire Fri, Jan 3, 2025, 12:05 AM 1 min read In This Article: AKBA -5.36% CAMBRIDGE, Mass. , Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics \u00ae , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia's common stock on December 31, 2024 . The options were granted as an inducement material to\u00a0the employee\u00a0entering into employment with Akebia.\u00a0The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.) The options have an exercise price of $1.90 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia's inducement award program and a stock option agreement covering the grant. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release. Akebia Therapeutics Contact Mercedes Carrasco mcarrasco@akebia.com Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302341489.html SOURCE Akebia Therapeutics, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AKBA", "date": "2025-01-03T00:05:00", "sentiment": {"score": 0.024112828075885773, "confidence": 0.03817975893616676, "probabilities": {"positive": 0.03817975893616676, "negative": 0.01406693086028099, "neutral": 0.9477533102035522}}, "embedding": [-0.11354056000709534, -0.026623379439115524, -0.042320337146520615, -0.042120784521102905, -0.18389424681663513, 0.04799274727702141, 0.10260534286499023, 0.08117979764938354, 0.1416892409324646, 0.08397363126277924, -0.05634436011314392, 0.05295279622077942, -0.051991499960422516, -0.009812048636376858, 0.0019191475585103035, 0.002831642050296068, 0.01758289709687233, 0.00946175679564476, -0.24701111018657684, 0.10890769958496094, -0.01697881706058979, -0.020503396168351173, -0.06059969961643219, -0.1386389434337616, 0.02945617027580738, -0.0030049101915210485, 0.03300287947058678, -0.0788160115480423, -0.09474803507328033, -0.07705476880073547, 0.09168748557567596, 0.0602458231151104, 0.06698331981897354, -0.21062487363815308, -0.006422626320272684, 0.07718618959188461, -0.2910465598106384, 0.059955038130283356, -0.023513667285442352, -0.023059748113155365, 0.06679660081863403, -0.05396471172571182, -0.04683668911457062, 0.010693604126572609, -0.1894548535346985, -0.07469374686479568, -0.049381811171770096, 0.003821199294179678, 0.07324934750795364, 0.11298757791519165, -0.16952109336853027, -0.16627666354179382, 0.028041595593094826, 0.07343246042728424, -0.04835958033800125, -0.07957150042057037, -0.20640337467193604, -0.058087415993213654, -0.011065036989748478, -0.003379411529749632, 0.022482188418507576, 0.05437042936682701, 0.06819228827953339, -0.007578480057418346, 0.09085533022880554, 0.016947656869888306, 0.12649652361869812, -0.12067075073719025, 0.06075053662061691, -0.12113431096076965, 0.16663725674152374, -0.045456357300281525, -0.01496807299554348, 0.06265044957399368, -0.0572875440120697, 0.12393452227115631, 0.08889758586883545, 0.1504790037870407, 0.15542641282081604, -0.18265846371650696, -0.017752790823578835, 0.11509422212839127, 0.08032366633415222, -0.04215234890580177, -0.039922330528497696, 0.02236402966082096, 0.01689363270998001, 0.08524780720472336, 0.12908513844013214, 0.04347557574510574, 0.16530698537826538, -0.00568089634180069, 0.10249529778957367, -0.12631888687610626, 0.025116760283708572, -0.1015818789601326, -0.11481299996376038, -0.04002020135521889, -0.039393700659275055, 0.04307030886411667, 0.018726499751210213, 0.05408826470375061, -0.09399806708097458, -0.03566097840666771, -0.015245314687490463, -0.1822969764471054, -0.03373425453901291, -0.07792254537343979, 0.026235118508338928, 0.10721109062433243, -0.14432168006896973, -0.038530249148607254, 0.02342183142900467, -0.03053274005651474, -0.08895101398229599, 0.0614701509475708, 0.0025615114718675613, -0.03161785751581192, 0.20388582348823547, -0.05645807832479477, 0.049899764358997345, 0.024170124903321266, -0.025748062878847122, -0.09085801243782043, -0.020163342356681824, 0.0552816167473793, -0.18940383195877075, 8.829689816687119e-33, -0.0069740270264446735, -0.0870070680975914, 0.11122880131006241, -0.05064810812473297, 0.040714871138334274, -0.06738469004631042, -0.035897981375455856, -0.025947831571102142, -0.06596739590167999, -0.07006725668907166, -0.23372063040733337, 0.07143962383270264, -0.008710319176316261, 0.016818108037114143, 0.008994911797344685, 0.0004956834018230438, -0.09029873460531235, 0.09093478322029114, 0.1391865611076355, 0.10228914022445679, 0.09021323919296265, 0.05376650393009186, -0.013107582926750183, 0.132245272397995, -0.006774762645363808, 0.013565405271947384, -0.03016512095928192, -0.00015928293578326702, -0.06584367901086807, 0.056349802762269974, -0.019215090200304985, -0.02453225664794445, -0.05750463157892227, -0.1786067932844162, -0.11167559027671814, -0.04221823066473007, -0.055180490016937256, -0.024598415940999985, -0.047387417405843735, 0.010789763182401657, -0.08969826996326447, -0.004714842885732651, -0.08987898379564285, -0.011735032312572002, 0.09375506639480591, -0.0015705239493399858, -0.10790644586086273, 0.07474300265312195, 0.0481933131814003, 0.09189428389072418, -0.09925690293312073, 0.007473183795809746, 0.07849651575088501, 0.010966058820486069, -0.03160303831100464, -0.030981894582509995, -0.11987203359603882, 0.09026890993118286, 0.10113589465618134, 0.0872817188501358, 0.0684695839881897, 0.13130050897598267, 0.06979037076234818, 0.07507534325122833, -0.09281694144010544, 0.09789460897445679, -0.02489081397652626, -0.0707164853811264, 0.05356805771589279, -0.08585084229707718, -0.02782556600868702, 0.09127116203308105, 0.1273972988128662, -0.034674447029829025, -0.10039891302585602, -0.11277519166469574, 0.07535417377948761, 0.01987801119685173, -0.013440481387078762, 0.04652131348848343, 0.026663726195693016, -0.05089619383215904, -0.008494405075907707, 0.11780906468629837, 0.09697677940130234, -0.013044039718806744, 0.03231123462319374, -0.004533568397164345, -0.2258884608745575, -0.10293640196323395, 0.1020490825176239, 0.08287807554006577, -0.17489764094352722, 0.21047215163707733, 0.13375045359134674, -9.254449557568967e-33, 0.1149592399597168, -0.04998012259602547, 0.030247822403907776, -0.053303539752960205, 0.05217926949262619, 0.05107347294688225, 0.08096659928560257, -0.01579691842198372, -0.003283437341451645, 0.05391434580087662, 0.01393797155469656, 0.050574056804180145, 0.018171334639191628, -0.02339506894350052, -0.1129857674241066, -0.016224347054958344, 0.03466944023966789, -0.03246568143367767, -0.0376395583152771, 0.01387600228190422, -0.05298899859189987, 0.15825015306472778, -0.10349774360656738, 0.09539280831813812, 0.0647193118929863, 0.015848439186811447, 0.027538783848285675, 0.1368587613105774, -0.07677982747554779, 0.03731679171323776, 0.03587930649518967, 0.07468947768211365, -0.3022609055042267, -0.006911280564963818, -0.10337512195110321, -0.17065030336380005, 0.16819386184215546, -0.1265997290611267, 0.07971832901239395, -0.020154111087322235, 0.158060684800148, 0.010199649259448051, 0.0604836568236351, 0.1254253089427948, 0.06560225784778595, -0.0662464052438736, 0.03552701324224472, -0.15349583327770233, 0.1677558869123459, -0.14341211318969727, 0.012376675382256508, -0.025052111595869064, 0.1172514259815216, 0.10791562497615814, -0.021563129499554634, -0.016119472682476044, 0.07240264117717743, 0.005456145852804184, -0.03263238072395325, -0.008798222057521343, 0.012877941131591797, 0.048162877559661865, 0.11772273480892181, -0.0044062258675694466, 0.030378032475709915, 0.07703765481710434, 0.16029223799705505, 0.0437135249376297, -0.016618937253952026, -0.09418990463018417, -0.036198657006025314, -0.17170743644237518, 0.07300668954849243, -0.08331558108329773, 0.10900728404521942, 0.1705637276172638, 0.09328387677669525, -0.12226442992687225, -0.024037931114435196, -0.043634071946144104, 0.011948964558541775, -0.1523449718952179, -0.042147666215896606, 0.0905853807926178, -0.009259680286049843, 0.04637892544269562, 0.07798344641923904, -0.031232420355081558, 0.02298758737742901, 0.07610403001308441, -0.10156440734863281, -0.07725921273231506, -0.05213005095720291, 0.11713168025016785, 0.010304431430995464, -1.0063187971809384e-07, 0.13863608241081238, -0.07836361229419708, -0.02616202086210251, -0.06820136308670044, 0.11019796878099442, -0.027921341359615326, -0.10341164469718933, 0.06169340759515762, -0.027006346732378006, 0.09828159213066101, 0.042507097125053406, 0.1798839271068573, -0.11978821456432343, 0.100597083568573, -0.0397396981716156, 0.03113352507352829, -0.10408623516559601, -0.0002787369303405285, -0.03125428408384323, -0.09085946530103683, -0.17600786685943604, -0.05676820129156113, 0.04121916741132736, -0.07705000042915344, 0.06087255850434303, -0.08162686228752136, 0.06822697818279266, -0.0055022574961185455, -0.01818494126200676, 0.016761966049671173, -0.07971209287643433, 0.046621255576610565, 0.09365727007389069, 0.019839651882648468, -0.07877594232559204, -0.06086815893650055, 0.10414035618305206, 0.041980668902397156, -0.020522644743323326, 0.05382185056805611, -0.07885976135730743, -0.05483834445476532, -0.03936343267560005, -0.052106939256191254, 0.05297401174902916, 0.06538034975528717, -0.2070673704147339, 0.03783171623945236, -0.061933454126119614, -0.17481467127799988, 0.029327623546123505, 0.09342849254608154, 0.01722816564142704, 0.09691058844327927, -0.06477287411689758, 0.14280664920806885, -0.12664422392845154, -0.05146649479866028, 0.024555787444114685, 0.04280191659927368, 0.10789929330348969, -0.0738019272685051, -0.006071366369724274, 0.04721105098724365], "changes": {"1wk": -5.789474509759633, "1mo": 17.894738823423122}}, {"text": "Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years editorial-team@simplywallst.com (Simply Wall St) Fri, Dec 20, 2024, 3:27 PM 2 min read In This Article: AKBA -5.36% Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders will doubtless be very grateful to see the share price up 31% in the last quarter. But spare a thought for the long term holders, who have held the stock as it bled value over the last five years. Five years have seen the share price descend precipitously, down a full 73%. It's true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The million dollar question is whether the company can justify a long term recovery. So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress. View our latest analysis for Akebia Therapeutics Akebia Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Over half a decade Akebia Therapeutics reduced its trailing twelve month revenue by 12% for each year. That puts it in an unattractive cohort, to put it mildly. So it's not altogether surprising to see the share price down 12% per year in the same time period. We don't think this is a particularly promising picture. Of course, the poor performance could mean the market has been too severe selling down. That can happen. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). NasdaqCM:AKBA Earnings and Revenue Growth December 20th 2024 You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic . A Different Perspective It's good to see that Akebia Therapeutics has rewarded shareholders with a total shareholder return of 49% in the last twelve months. There's no doubt those recent returns are much better than the TSR loss of 12% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. It's always interesting to track share price performance over the longer term. But to understand Akebia Therapeutics better, we need to consider many other factors. For instance, we've identified 3 warning signs for Akebia Therapeutics (2 are concerning) that you should be aware of. For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Story Continues Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AKBA", "date": "2024-12-20T15:27:05", "sentiment": {"score": -0.9010404497385025, "confidence": 0.9337805509567261, "probabilities": {"positive": 0.03274010121822357, "negative": 0.9337805509567261, "neutral": 0.03347938880324364}}, "embedding": [-0.05632668733596802, -0.10908956825733185, 0.012002609670162201, 0.042394958436489105, -0.05086603760719299, 0.027093572542071342, -0.03863070532679558, 0.08132365345954895, 0.13019023835659027, 0.09870591759681702, -0.15188100934028625, 0.13482743501663208, -0.015350733883678913, -0.031115759164094925, -0.054141752421855927, -0.07111398875713348, -0.005018916912376881, -0.020041167736053467, -0.11912798881530762, 0.05246860161423683, -0.13717369735240936, -0.08005251735448837, -0.0011151046492159367, -0.03292535990476608, 0.04113984853029251, 0.006193734705448151, -0.03905747830867767, -0.019118698313832283, -0.15929493308067322, -0.11273545026779175, -0.005437595769762993, 0.08064760267734528, 0.053244635462760925, -0.06187635287642479, -0.06817421317100525, 0.018038582056760788, -0.16461434960365295, 0.07524275779724121, 0.101376011967659, -0.037633128464221954, 0.06138124316930771, -0.03455217182636261, -0.07086648046970367, -0.04212573543190956, -0.1673169732093811, -0.14780157804489136, -0.031197473406791687, -0.02775627002120018, 0.031183499842882156, 0.13329923152923584, -0.1837562620639801, -0.1306266337633133, 0.04734029248356819, -0.045726366341114044, -0.04564566910266876, 0.01266726478934288, -0.18844789266586304, -0.06681286543607712, -0.0054079387336969376, -0.012802915647625923, 0.10184691101312637, 0.0681789293885231, 0.06391680985689163, 0.009198939427733421, 0.16978082060813904, -0.0034634307958185673, 0.1327487677335739, 0.029963497072458267, -0.029372744262218475, 0.03486566245555878, 0.19195739924907684, -0.04752577841281891, -0.03930175304412842, -0.024981047958135605, -0.13126379251480103, 0.07324296236038208, 0.09009049087762833, 0.1192861944437027, 0.1023724302649498, -0.032881975173950195, 0.08603740483522415, 0.0715114027261734, -0.04602824151515961, -0.07199050486087799, -0.06852665543556213, 0.01772867701947689, 0.18573316931724548, -0.06791207194328308, 0.039530232548713684, 0.011789648793637753, 0.19061484932899475, 0.08098654448986053, 0.045745790004730225, -0.039688967168331146, 0.0673467144370079, 0.009446399286389351, -0.08681058883666992, -0.024095339700579643, 0.0028621703386306763, 0.07665631175041199, 0.079004667699337, 0.20767763257026672, -0.03512120246887207, -0.16569799184799194, -0.03406231105327606, -0.1825462281703949, 0.04370293766260147, -0.047243453562259674, -0.03473968431353569, 0.11018399894237518, -0.11744897067546844, 0.08454298228025436, -0.0760340616106987, -0.0005344774108380079, 0.024240192025899887, -0.05069597810506821, -0.061540387570858, -0.05900213122367859, 0.06303271651268005, 0.09481623023748398, 0.08168592303991318, 0.08861979097127914, -0.022959880530834198, -0.018536781892180443, 0.05399874225258827, 0.0788903683423996, -0.09709152579307556, 1.3068414447208806e-32, 0.029233695939183235, -0.04069359600543976, 0.08248698711395264, -0.06433354318141937, -0.018657894805073738, -0.05512310191988945, -0.0939837247133255, -0.04546450078487396, -0.06750668585300446, -0.0986369177699089, -0.21465632319450378, 0.08516214787960052, -0.012494100257754326, -0.09591329097747803, 0.007119707763195038, -0.04410335049033165, -0.043908096849918365, 0.01746976189315319, 0.06993012130260468, -0.061691462993621826, -0.05408913269639015, 0.04301551729440689, -0.015857066959142685, 0.03291131183505058, -0.004938814789056778, 0.044176019728183746, -0.03796597942709923, 0.09600979089736938, -0.11238308250904083, 0.05609189346432686, 0.012495853938162327, 0.007709410972893238, -0.08835846185684204, -0.11635053157806396, -0.12507490813732147, -0.10975377261638641, -0.05574691668152809, 0.06823968142271042, 0.06478674709796906, 0.022650012746453285, -0.11705602705478668, 0.06494147330522537, -0.16460658609867096, 0.03150127828121185, -0.0006455788388848305, 0.004624553024768829, -0.0507141649723053, -0.023919671773910522, -0.09817524999380112, 0.04527182877063751, -0.03362606465816498, 0.010965414345264435, 0.010389730334281921, 0.007267031818628311, 0.014029632322490215, 0.07951433211565018, -0.015281626023352146, -0.060493096709251404, 0.05854981392621994, 0.08822319656610489, 0.125614732503891, 0.13603216409683228, 0.03815434128046036, 0.012683534994721413, -0.17811624705791473, 0.19270017743110657, 0.043953970074653625, 0.0032196128740906715, -0.0871674120426178, 0.07311531901359558, -0.009071609936654568, 0.03442943096160889, 0.04474809393286705, -0.07748131453990936, 0.08989588171243668, -0.07127803564071655, 0.04580102860927582, -0.01665024273097515, 0.031678181141614914, 0.07312554121017456, 0.042912062257528305, -0.07992926985025406, 0.08887329697608948, 0.02813597023487091, -0.012857465073466301, -0.0032936311326920986, 0.1179470419883728, -0.0333995446562767, -0.16228176653385162, -0.02927936613559723, 0.06782916933298111, -0.021090535447001457, -0.07098830491304398, 0.1751348376274109, 0.08879221975803375, -1.1809232980131633e-32, 0.08577663451433182, 0.033926937729120255, 0.025990378111600876, -0.06892931461334229, -0.04956938326358795, -0.05007510632276535, 0.0749916136264801, 0.10828407108783722, -0.10750527679920197, 0.0387660376727581, 0.041429877281188965, 0.03901662304997444, -0.06913246214389801, 0.12157891690731049, -0.0898539125919342, -0.014273441396653652, 0.25244200229644775, -0.04534474015235901, -0.034807056188583374, -0.12368173897266388, 0.003488176967948675, 0.19968938827514648, -0.10578922927379608, 0.020784396678209305, -0.026243722066283226, 0.09799746423959732, 0.05635832995176315, 0.09260941296815872, -0.0911509320139885, -0.07574868202209473, 0.042621128261089325, -0.020827075466513634, -0.10581617802381516, -0.023030728101730347, -0.06971128284931183, -0.0416983962059021, 0.043441034853458405, -0.23223498463630676, -0.056624025106430054, -0.05234507843852043, 0.16792604327201843, 0.12034285068511963, 0.01585325226187706, 0.0213250033557415, 0.11761162430047989, -0.03720252215862274, 0.11287536472082138, -0.025326412171125412, 0.21214425563812256, 0.025886651128530502, 0.0808458924293518, -0.03015766479074955, -0.018656747415661812, 0.098143070936203, -0.006654382683336735, 0.052286818623542786, -0.00977412611246109, -0.045836348086595535, -0.14762943983078003, 0.03927314653992653, -0.08663997799158096, 0.04516500234603882, 0.044520262628793716, -0.017467763274908066, 0.04586268588900566, 0.06594930589199066, 0.126314178109169, -0.06891186535358429, 0.02353302761912346, -0.03813324496150017, 0.016717424616217613, -0.06763989478349686, -0.08880140632390976, -0.05657967925071716, 0.025093991309404373, 0.2819437086582184, -0.04641962796449661, -0.02781209535896778, -0.026539679616689682, 0.008767968975007534, -0.0329708456993103, -0.0674533098936081, -0.028300529345870018, 0.03643319010734558, -0.07126171886920929, 0.07803033292293549, -0.005081283859908581, -0.09188634902238846, -0.014529422856867313, 0.08109614253044128, -0.0194469653069973, -0.22599561512470245, -0.11508727073669434, 0.06970108300447464, 0.11177957057952881, -1.0053379639884952e-07, 0.07152535021305084, -0.046533867716789246, -0.016360068693757057, -0.0014476832002401352, 0.1572016477584839, -0.07867898046970367, -0.005660749971866608, -0.015544578433036804, 0.08853809535503387, 0.12169159203767776, 0.06142624467611313, 0.07929021120071411, -0.18837067484855652, 0.10264015942811966, -0.08649548888206482, 0.08580777794122696, -0.14460687339305878, 0.03847675025463104, -0.06101594120264053, -0.14494141936302185, -0.07850184291601181, 0.048840951174497604, 0.13485777378082275, -0.038951270282268524, 0.05212373286485672, -0.029031667858362198, -0.06597866117954254, 0.018696051090955734, -0.08448760956525803, -0.028121910989284515, 0.022945823147892952, -0.045339517295360565, 0.08637094497680664, -0.0417325384914875, -0.012621426954865456, -0.03159290552139282, 0.0916205644607544, 0.0653124526143074, 0.01047999132424593, 0.12222804874181747, -0.10917700827121735, 0.005763442255556583, -0.04269888252019882, 0.019820459187030792, -0.001771862618625164, -0.013690096326172352, -0.09215204417705536, 0.09323237836360931, -0.014588123187422752, -0.2817084789276123, 0.09851090610027313, -0.026068400591611862, 0.005093855783343315, 0.12253443896770477, -0.005914696492254734, 0.0374603271484375, -0.1655736267566681, 0.033597320318222046, -0.17398598790168762, 0.06122419983148575, 0.025476550683379173, -0.18164438009262085, -0.02893456257879734, 0.11653359979391098], "changes": {"1wk": 5.464475534834419, "1mo": 13.114747797771281}}, {"text": "Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates Zacks Equity Research Thu, Nov 7, 2024, 4:15 PM 3 min read In This Article: AKBA -5.36% Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.06 per share when it actually produced a loss of $0.04, delivering a surprise of 33.33%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Akebia Therapeutics , which belongs to the Zacks Medical - Drugs industry, posted revenues of $37.43 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 18.03%. This compares to year-ago revenues of $42.05 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Akebia Therapeutics shares have added about 61.3% since the beginning of the year versus the S&P 500's gain of 24.3%. What's Next for Akebia Therapeutics? While Akebia Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Akebia Therapeutics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.03 on $55.14 million in revenues for the coming quarter and -$0.19 on $177.06 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Addex Therapeutics Ltd. Sponsored ADR (ADXN), another stock in the same industry, has yet to report results for the quarter ended September 2024. The results are expected to be released on November 11. This company is expected to post quarterly loss of $1.40 per share in its upcoming report, which represents a year-over-year change of +65.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Addex Therapeutics Ltd. Sponsored ADR's revenues are expected to be $0.13 million, down 64.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Akebia Therapeutics, Inc. (AKBA) : Free Stock Analysis Report Addex Therapeutics Ltd. Sponsored ADR (ADXN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AKBA", "date": "2024-11-07T16:15:10", "sentiment": {"score": -0.20031045377254486, "confidence": 0.3447076380252838, "probabilities": {"positive": 0.14439718425273895, "negative": 0.3447076380252838, "neutral": 0.5108951926231384}}, "embedding": [-0.11150462180376053, -0.041913729161024094, -0.06378600001335144, 0.08481138199567795, -0.10698364675045013, -0.01109740324318409, 0.01095569971948862, 0.1465999186038971, 0.2514699399471283, 0.12150202691555023, -0.1885417103767395, 0.11316834390163422, -0.02431020513176918, -0.07626546919345856, -0.09102985262870789, -0.011482182890176773, 0.09008729457855225, 0.001493772491812706, -0.1742183268070221, 0.05307227373123169, -0.0557122528553009, 0.01244947500526905, 0.11056920886039734, 0.0022704219445586205, 0.12306436896324158, 0.045686542987823486, -0.05346899852156639, -0.04026191309094429, -0.18762382864952087, -0.15460073947906494, -0.02530268393456936, 0.08699629455804825, 0.09989497810602188, -0.17690348625183105, -0.046698182821273804, -0.012831314466893673, -0.1909097582101822, 0.12993237376213074, 0.057958848774433136, -0.03741857782006264, 0.05383157730102539, 0.006181484553962946, -0.14542128145694733, -0.029994074255228043, -0.17058834433555603, -0.19834259152412415, -0.07302771508693695, -0.017215941101312637, 0.08051872253417969, 0.18379847705364227, -0.27086785435676575, -0.22051286697387695, 0.06505252420902252, 0.050752073526382446, -0.10795491188764572, -0.06773821264505386, -0.19710145890712738, -0.06679584830999374, 0.04559459164738655, 0.09428900480270386, 0.09144169092178345, 0.0718417540192604, 0.03202778846025467, 0.03816675394773483, 0.17708590626716614, -0.02743358537554741, 0.11119449138641357, -0.013144709169864655, -0.05509226769208908, -0.011422531679272652, 0.1608525514602661, -0.013047735206782818, -0.030085761100053787, 0.044573865830898285, -0.11865058541297913, 0.005131596699357033, 0.12892577052116394, 0.14471083879470825, 0.13273540139198303, -0.035368092358112335, 0.06769756972789764, 0.0026508187875151634, -0.014349963515996933, -0.055963873863220215, 0.013973776251077652, 0.023314395919442177, 0.148237943649292, 0.13988211750984192, 0.08675284683704376, 0.05751703679561615, 0.08900800347328186, -0.02649127133190632, 0.08926889300346375, -0.09800061583518982, 0.07456286251544952, -0.011337408795952797, -0.1078176498413086, -0.10034044086933136, 0.03686687350273132, 0.061835162341594696, 0.10197719931602478, 0.15165385603904724, -0.03603681921958923, -0.14721542596817017, 0.055430345237255096, -0.18314780294895172, 0.03842025250196457, -0.07023707032203674, -0.0034343162551522255, 0.127701997756958, -0.07428467273712158, 0.016536731272935867, -0.1078958660364151, 0.0017966112354770303, -0.0005559846758842468, 0.0364544503390789, 0.0025699734687805176, 0.08313114196062088, 0.08244612067937851, 0.14134904742240906, 0.04649445042014122, 0.0548027902841568, 0.02675517275929451, -0.04405837506055832, 0.008439257740974426, 0.12027933448553085, -0.18272146582603455, 8.382424501774808e-33, 0.0839836448431015, 0.011972131207585335, 0.07109576463699341, -0.07566066086292267, -0.004909681621938944, -0.03990660980343819, -0.05663827806711197, -0.08351262658834457, -0.004502288531512022, -0.16416434943675995, -0.26068753004074097, 0.06057354435324669, -0.017404859885573387, -0.03711865097284317, 0.003779873251914978, -0.023517530411481857, -0.08062943071126938, 0.08945086598396301, 0.08950664848089218, 0.0492081418633461, 0.009326954372227192, -0.043313078582286835, -0.04306070879101753, 0.09410370886325836, -0.09861297160387039, 0.10319644957780838, -0.07508575916290283, 0.06682628393173218, -0.17056164145469666, 0.04158578813076019, -0.05558478832244873, 0.0027561383321881294, 0.005585984326899052, -0.19515733420848846, -0.16643227636814117, -0.06633642315864563, -0.04127088189125061, -0.009391847997903824, 0.10061298310756683, 0.05425934121012688, -0.10770240426063538, 0.10305143147706985, -0.1748349368572235, -0.09231390804052353, 0.0021390607580542564, -0.0057798121124506, -0.09617753326892853, 0.0104256896302104, -0.02841895818710327, 0.005147670395672321, -0.07898516952991486, 0.018696557730436325, 0.09470739960670471, 0.04531824588775635, -0.019175898283720016, 0.012157458811998367, -0.07070048898458481, -0.09290118515491486, 0.05772518739104271, 0.13707196712493896, 0.15114985406398773, 0.22834378480911255, 0.10251788794994354, 0.008660157211124897, -0.20538313686847687, 0.18012955784797668, 0.05601317435503006, 0.05483366176486015, -0.09874219447374344, 0.08932521939277649, -0.023210816085338593, 0.018467675894498825, 0.10024382174015045, -0.02494070678949356, 0.10267872363328934, -0.08740808069705963, -0.0007934849709272385, -0.05759652704000473, 0.05176032334566116, 0.08051300793886185, 0.06933790445327759, -0.05678064003586769, -0.011537712067365646, 0.11677627265453339, 0.05102192983031273, -0.026428868994116783, 0.052036795765161514, 0.026949560269713402, -0.11381033062934875, -0.06988542526960373, 0.06907826662063599, -0.04617975279688835, -0.14956584572792053, 0.15052887797355652, 0.04767914488911629, -9.059856753365907e-33, 0.040426142513751984, 0.08195362240076065, 0.03720363974571228, -0.0377548448741436, -0.04979929327964783, -0.017267078161239624, 0.06352423131465912, 0.10645019263029099, 0.02069486863911152, 0.03601330146193504, 0.04734388738870621, 0.02795429900288582, -0.13182999193668365, 0.0755806565284729, -0.07947082817554474, -0.048438478261232376, 0.1127316802740097, -0.12933465838432312, 0.022920971736311913, -0.1301104575395584, 0.02273186668753624, 0.2163938581943512, -0.12372875958681107, 0.09925326704978943, 0.026278287172317505, 0.02171999029815197, 0.018480995669960976, 0.13596467673778534, -0.08668111264705658, -0.04081001877784729, 0.10549961030483246, -0.030939891934394836, -0.22331133484840393, -0.01852157898247242, -0.07867743074893951, -0.06204669922590256, 0.029627934098243713, -0.17981742322444916, -0.009760326705873013, -0.08729982376098633, 0.2121182680130005, 0.06102538853883743, 0.024941498413681984, 0.04830454662442207, 0.07165759056806564, -0.033691488206386566, 0.05938352644443512, -0.033842626959085464, 0.2406778186559677, -0.061940159648656845, 0.01661558263003826, -0.020949216559529305, -0.04013323783874512, 0.13183772563934326, -0.11586529016494751, -0.00026553496718406677, -0.04933241009712219, -0.002887656446546316, -0.16492235660552979, 0.024629423394799232, -0.09114623069763184, 0.05477475747466087, 0.09986409544944763, 0.023247133940458298, -0.0022712498903274536, 0.11720951646566391, 0.16386514902114868, 0.053107451647520065, -0.005587243475019932, -0.10462823510169983, 0.035192422568798065, -0.0683998316526413, 0.07721007615327835, -0.05070505663752556, 0.04864669591188431, 0.29833826422691345, -0.020007949322462082, -0.1506180614233017, -0.03626237064599991, -0.06596501916646957, 0.08767784386873245, -0.0708913654088974, -0.030392978340387344, -0.0007370088715106249, -0.08917304873466492, 0.14190396666526794, 0.05673778057098389, -0.08646393567323685, -0.04935178905725479, 0.04943745955824852, -0.05745892971754074, -0.23216566443443298, -0.15793439745903015, 0.05686531588435173, 0.11689034849405289, -1.0054576193851972e-07, 0.1409820318222046, -0.053222574293613434, 0.028084825724363327, -0.021981574594974518, 0.08365759253501892, -0.025122150778770447, -0.07287231087684631, 0.044591087847948074, 0.07136297225952148, 0.09820549190044403, 0.04554174095392227, 0.08958631753921509, -0.1917877197265625, 0.09963473677635193, -0.08775059133768082, 0.06980697065591812, -0.06015850603580475, 0.10115405917167664, -0.008596237748861313, -0.1906595081090927, -0.15832148492336273, 0.013380148448050022, 0.1618104875087738, -0.1893922984600067, 0.09503798186779022, -0.11558164656162262, -0.07052828371524811, -0.04523353651165962, -0.02443655952811241, -0.00982077606022358, 0.04784322530031204, -0.01170027069747448, 0.10720500349998474, 0.06171330064535141, -0.03196007385849953, -0.1310826689004898, 0.08217784762382507, 0.034847673028707504, 0.005473563447594643, 0.08041663467884064, -0.08597028255462646, -0.05055882781744003, -0.05286179855465889, 0.004545504227280617, -0.02190244011580944, -0.010759955272078514, -0.11900131404399872, 0.04492994770407677, -0.03990806266665459, -0.3118765950202942, 0.12511518597602844, -0.016256511211395264, 0.05546189844608307, 0.038205068558454514, 0.031420595943927765, 0.11954890936613083, -0.17234393954277039, -0.032711710780858994, -0.142133891582489, -0.004296079743653536, 0.11932054907083511, -0.2049523890018463, 0.016173185780644417, 0.09800003468990326], "changes": {"1wk": 2.9490588346739104, "1mo": 9.919567926731222}}, {"text": "New Strong Sell Stocks for December 5th Zacks Equity Research Thu, Dec 5, 2024, 1:46 PM 1 min read In This Article: AKBA -5.36% KOF -1.54% Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Akebia Therapeutics, Inc. AKBA is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 26.3% downward over the last 60 days. Coca-Cola FEMSA, S.A.B. de C.V. KOF is a franchise bottler company. The Zacks Consensus Estimate for its current year earnings has been revised 10.5% downward over the last 60 days. DENTSPLY SIRONA Inc. XRAY is a dental products company.The Zacks Consensus Estimate for its current year earnings has been revised 6.5% downward over the last 60 days. View the entire Zacks Rank #5 List. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report Coca Cola Femsa S.A.B. de C.V. (KOF) : Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AKBA", "date": "2024-12-05T13:46:00", "sentiment": {"score": -0.3595158997923136, "confidence": 0.38547465205192566, "probabilities": {"positive": 0.025958752259612083, "negative": 0.38547465205192566, "neutral": 0.5885666012763977}}, "embedding": [-0.21787570416927338, -0.21081221103668213, -0.13293562829494476, 0.049993161112070084, -0.08046169579029083, 0.014289917424321175, -0.0534454807639122, 0.13580010831356049, -0.03058800846338272, 0.04917808994650841, -0.09916563332080841, 0.12325199693441391, -0.05535091459751129, 0.005216807592660189, -0.033700671046972275, -0.00463393097743392, 0.10531750321388245, -0.04595343768596649, -0.16024348139762878, 0.02084108255803585, -0.0600518062710762, -0.08738973736763, 0.13532382249832153, -0.0500435046851635, 0.03216305375099182, 0.11770112067461014, -0.08500776439905167, -0.02741781808435917, -0.1082562580704689, -0.1652947962284088, -0.11524321883916855, 0.08501456677913666, 0.16776177287101746, -0.14812472462654114, -0.03783338516950607, 0.0267960112541914, -0.10875041037797928, 0.06462439894676208, 0.20340092480182648, -0.050296518951654434, 0.038486823439598083, -0.004575943574309349, -0.0723678395152092, -0.1263301819562912, -0.15123705565929413, -0.13824403285980225, -0.062374550849199295, 0.03619533032178879, 0.15849539637565613, 0.06556052714586258, -0.24643824994564056, -0.1384831815958023, 0.10612528026103973, -0.05177847668528557, -0.11797039955854416, -0.024995403364300728, -0.14864297211170197, -0.2052086889743805, 0.09314233064651489, 0.06219802051782608, 0.22207678854465485, 0.03291180357336998, 0.05966001749038696, 0.14531515538692474, 0.034276898950338364, -0.013741949573159218, 0.047355953603982925, 0.016617301851511, -0.0619552880525589, 0.02847348526120186, 0.08989512175321579, -0.07434219866991043, -0.015793409198522568, 0.08606637269258499, -0.0723838210105896, 0.02408788539469242, 0.195550799369812, 0.012223029509186745, 0.11092796176671982, -0.01971888169646263, 0.021661486476659775, 0.025294598191976547, 0.011645297519862652, -0.026748156175017357, -0.03672907501459122, 0.003157973289489746, 0.020065004006028175, 0.0314236581325531, 0.03783481940627098, 0.059428684413433075, 0.13670113682746887, 0.0960271954536438, 0.0766398087143898, -0.09832647442817688, -0.06988577544689178, -0.04075389355421066, -0.08094959706068039, 0.10146506130695343, -0.0619327537715435, 0.07183249294757843, 0.016007723286747932, 0.1875889003276825, -0.07201984524726868, -0.06570452451705933, 0.01851469650864601, -0.2099626362323761, 0.047871824353933334, -0.022006718441843987, 0.003486413974314928, 0.20218650996685028, -0.09674826264381409, 0.08358977735042572, -0.06387410312891006, 0.003590445499867201, -0.1269042193889618, 0.0045363036915659904, 0.0016839291201904416, 0.07501012086868286, 0.1395278424024582, 0.040113192051649094, 0.06863562017679214, 0.1140352413058281, -0.010263676755130291, -0.07786577939987183, 0.02152092382311821, 0.024392982944846153, -0.18159854412078857, 1.039603236573797e-32, -0.027180589735507965, 0.11845219135284424, 0.13524030148983002, -0.07472464442253113, -0.01745764911174774, -0.03170151636004448, -0.013909603469073772, 0.010706780478358269, -0.09690506011247635, 0.001899742754176259, -0.16059771180152893, 0.10088641196489334, -0.06758108735084534, -0.053277429193258286, -0.027908889576792717, -0.025926366448402405, -0.06323724240064621, -0.03341909870505333, 0.0033571897074580193, -0.05835086852312088, 0.10340385884046555, -0.031107837334275246, -0.02386479824781418, 0.08900181204080582, -0.023479079827666283, -0.0578383207321167, -0.04613571986556053, 0.03789184242486954, -0.1602557897567749, 0.1035863608121872, -0.0701482892036438, -0.018375027924776077, -0.03896304592490196, -0.06959010660648346, -0.13706283271312714, -0.1108376756310463, -0.10782607644796371, -0.04574563354253769, 0.05985596030950546, -0.03193332254886627, -0.0852845162153244, 0.12207552790641785, -0.15568698942661285, -0.01062528882175684, -0.07468312233686447, 0.09837844222784042, -0.21271219849586487, 0.06562690436840057, 0.14153487980365753, 0.042592115700244904, -0.16343729197978973, -0.0697958692908287, -0.045881714671850204, 0.08319249749183655, -0.04727281630039215, 0.0680861696600914, -0.02632302977144718, -0.10189111530780792, 0.01874329335987568, 0.06508486717939377, -0.005964379757642746, 0.14654134213924408, 0.03172929584980011, -0.05271671339869499, -0.2021767944097519, 0.07652096450328827, -0.009774796664714813, 0.06284111738204956, -0.04691227152943611, 0.037760671228170395, 0.05851580947637558, 0.10199908167123795, 0.1277015656232834, -0.08248865604400635, 0.10195326060056686, -0.05569402500987053, 0.10978361964225769, 0.02749643288552761, 0.06237015873193741, 0.09038001298904419, 0.17638656497001648, -0.00837614480406046, 0.07146208733320236, 0.09933546930551529, 0.026530848816037178, -0.02413978986442089, 0.02959424816071987, -0.022275766357779503, -0.02506488934159279, -0.012875589542090893, 0.019416555762290955, -0.06976903229951859, -0.06802776455879211, 0.02116077020764351, -0.03778978809714317, -1.1179715347647989e-32, 0.08874718099832535, -0.0024428132455796003, 0.11560393124818802, -0.0195982214063406, -0.03303290158510208, -0.03405403718352318, 0.027647104114294052, 0.1460423469543457, 0.038890112191438675, -0.02579486556351185, 0.12130141258239746, 0.12483654171228409, -0.031912174075841904, -0.02258748561143875, -0.02343878336250782, 0.023258907720446587, 0.15943951904773712, -0.07758874446153641, -0.05016046762466431, -0.12496806681156158, 0.05503809452056885, 0.15156006813049316, -0.17862024903297424, 0.16014230251312256, 0.027644598856568336, 0.02804575487971306, -0.04632952809333801, 0.08808243274688721, -0.012393301352858543, 0.09703028947114944, 0.017376184463500977, 0.04191342368721962, -0.13932806253433228, 0.11821451038122177, -0.09241045266389847, -0.07244674116373062, 0.034778278321027756, -0.18194206058979034, -0.04418756440281868, -0.0877012237906456, 0.13670101761817932, 0.1492428183555603, -0.04719448834657669, 0.02580861933529377, 0.09797187149524689, 0.02559416927397251, 0.05703447014093399, -0.029497871175408363, 0.20499052107334137, 0.0039885262958705425, -0.005254466086626053, 0.04075322300195694, -0.12559504806995392, 0.18310843408107758, -0.12352745980024338, 0.011636384762823582, 0.1103774905204773, 0.0036682209465652704, -0.23308737576007843, 0.022303009405732155, -0.010177810676395893, 0.1388130486011505, 0.014447871595621109, 0.038875795900821686, -0.02845308557152748, 0.005124568473547697, 0.10634887218475342, 0.06165819987654686, 0.009578785859048367, -0.1522514373064041, 0.0044146873988211155, -0.09338752180337906, 0.08621945977210999, -0.11291098594665527, -0.0886918231844902, 0.26735684275627136, -0.09362085163593292, -0.15908651053905487, -0.12144012004137039, 0.05020836740732193, 0.12099635601043701, -0.006412349175661802, -0.028617611154913902, 0.1258845329284668, 0.054657548666000366, 0.12019258737564087, 0.02554982155561447, -0.09161476045846939, 0.013786910101771355, 0.05993635952472687, -0.09101790189743042, -0.16912329196929932, -0.13694843649864197, 0.11480937898159027, 0.16892534494400024, -9.975317993848876e-08, 0.13366730511188507, -0.10384233295917511, -0.018874306231737137, -0.023830773308873177, 0.09767737239599228, -0.008590780198574066, -0.13561759889125824, -0.05465671792626381, 0.14564746618270874, 0.08343013375997543, 0.09544159471988678, 0.08352313190698624, -0.22344137728214264, 0.09410553425550461, -0.15108343958854675, -0.03542081266641617, -0.08667761087417603, 0.09939920157194138, 0.010085449554026127, -0.15924319624900818, -0.1344260722398758, 0.03245970234274864, 0.19749966263771057, -0.11087722331285477, 0.053884100168943405, -0.06256766617298126, -0.12888993322849274, -0.06375064700841904, 0.004988779313862324, 0.011641230434179306, -0.02999308332800865, 0.05414092540740967, 0.08070293813943863, 0.0660671815276146, 0.04653508588671684, -0.05183432251214981, 0.045665424317121506, -0.032914455980062485, -0.09827545285224915, 0.1026415303349495, -0.03000708483159542, -0.12815596163272858, -0.16248801350593567, 0.048556458204984665, 0.018734557554125786, 0.01701323315501213, -0.052840251475572586, 0.04962284117937088, 0.12212423980236053, -0.19394433498382568, 0.08567429333925247, -0.02416939102113247, 0.0333072692155838, 0.02144818939268589, -0.041765157133340836, 0.1915782392024994, -0.19702892005443573, -0.014456722885370255, -0.031983740627765656, 0.03503045439720154, 0.08861015737056732, -0.2723409831523895, 0.052611399441957474, 0.1334032565355301], "changes": {"1wk": -4.950496276539116, "1mo": -4.950496276539116}}, {"text": "Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire Wed, Dec 18, 2024, 4:00 PM 1 min read In This Article: AKBA -5.36% CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Akebia Therapeutics \u00ae , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2024 at 7:30 AM PST . Among other business updates, Mr. Butler will discuss the Vafseo\u00ae (vadadustat) U.S. launch. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.) A webcast of the presentation can be accessed through the \"Investors\" section of Akebia's website at https://ir.akebia.com following the conference. The J.P. Morgan Healthcare Conference will take place January 13-16, 2025 in San Francisco . About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release. Akebia Therapeutics Contact Mercedes Carrasco mcarrasco@akebia.com Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334295.html SOURCE Akebia Therapeutics, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AKBA", "date": "2024-12-18T16:00:00", "sentiment": {"score": 0.006172170862555504, "confidence": 0.030060647055506706, "probabilities": {"positive": 0.030060647055506706, "negative": 0.023888476192951202, "neutral": 0.9460509419441223}}, "embedding": [-0.10747703164815903, -0.1055501401424408, -0.060612160712480545, -0.027398454025387764, -0.12853345274925232, 0.007023857906460762, 0.011226317845284939, 0.0550069734454155, 0.1053919792175293, 0.014028324745595455, -0.12118206173181534, 0.08265922963619232, -0.0990668311715126, -0.05555117502808571, 0.007333748508244753, -0.04351043701171875, 0.14210571348667145, 0.06075514853000641, -0.17494645714759827, 0.09516927599906921, 0.018722940236330032, 0.049745503813028336, 0.010555204004049301, -0.06763502955436707, -0.041720930486917496, 0.00560269458219409, -0.013295958749949932, -0.12979048490524292, -0.1526135355234146, -0.09851881116628647, 0.022722525522112846, 0.010389593429863453, 0.06744038313627243, -0.10204438865184784, 0.04625101387500763, 0.0901198759675026, -0.20343175530433655, 0.05879217013716698, -0.05542045459151268, -0.12204599380493164, 0.05313853174448013, -0.07813593745231628, -0.008002188056707382, -0.02737312950193882, -0.13431623578071594, -0.0599738173186779, -0.031739722937345505, -0.020839450880885124, 0.047094181180000305, 0.11894271522760391, -0.22059474885463715, -0.19751228392124176, 0.0814618319272995, 0.035714104771614075, -0.08791645616292953, -0.04042017459869385, -0.19361817836761475, -0.07840671390295029, -0.009454693645238876, -0.0956488847732544, -0.0157316867262125, 0.05852430686354637, 0.08534316718578339, 0.008266530930995941, 0.05873355641961098, 0.07779786735773087, 0.1311773657798767, -0.08952111750841141, 0.07222432643175125, -0.1948041319847107, 0.12651079893112183, -0.04478147625923157, 0.049347031861543655, 0.14859992265701294, -0.022414857521653175, 0.07519712299108505, 0.08610564470291138, 0.12291678786277771, 0.20761042833328247, -0.04989124834537506, 0.061790406703948975, 0.1297607272863388, 0.09580884873867035, 0.03707995265722275, -0.04376692697405815, 0.05837128683924675, -0.015570184215903282, 0.10666266828775406, 0.021814245730638504, 0.021797427907586098, 0.11559063196182251, 0.035450149327516556, 0.11523812264204025, -0.025749506428837776, 0.0003228451241739094, -0.10068947076797485, -0.059603653848171234, -0.0342937670648098, 0.019131261855363846, 0.049179259687662125, -0.04028244689106941, 0.1461908221244812, -0.03892439976334572, -0.04001009836792946, -0.004006095230579376, -0.08476588129997253, -0.06944474577903748, 0.0018626517849043012, 0.0357598252594471, 0.08595101535320282, -0.09226977080106735, 0.018605021759867668, 0.017447352409362793, -0.07547077536582947, -0.014452686533331871, 0.05363187566399574, 0.019877253100275993, 0.015834301710128784, 0.16162322461605072, -0.011173578910529613, 0.023701220750808716, 0.037140101194381714, -0.04357569292187691, -0.0843968316912651, -0.008772213011980057, 0.11197078973054886, -0.1408357471227646, 7.395021736711564e-33, -0.0010744314640760422, -0.029889795929193497, 0.2049020677804947, 0.04066382348537445, 0.042597465217113495, 0.009044830687344074, -0.046127717941999435, -0.07263930141925812, -0.066204734146595, -0.15377353131771088, -0.16195885837078094, 0.0283926110714674, 0.024020813405513763, 0.07119309902191162, -0.09033670276403427, -0.004263790789991617, -0.10202618688344955, 0.05164046585559845, 0.12817557156085968, 0.052324775606393814, 0.04501708969473839, 0.02107345126569271, 0.03178521990776062, 0.11077714711427689, -0.06328701227903366, 0.026450393721461296, -0.02751152776181698, 0.07102710008621216, -0.00835641473531723, 0.10062314569950104, -0.12068957835435867, 0.009020821191370487, -0.03606371209025383, -0.17273934185504913, -0.12419550120830536, -0.02476184442639351, -0.085965096950531, -0.12102005630731583, -0.06853386014699936, 0.03332352638244629, -0.10895772278308868, 0.059675559401512146, -0.14094160497188568, -0.00724767055362463, 0.12594185769557953, -0.04801437258720398, -0.11141102761030197, 0.022782783955335617, 0.06403344869613647, -0.004043044522404671, -0.12207597494125366, -0.03418445214629173, 0.09778234362602234, -0.015566520392894745, 0.06468208879232407, -0.03776437044143677, -0.06812825053930283, 0.0163573045283556, 0.06925684213638306, 0.06225193664431572, 0.09627430886030197, 0.15546248853206635, 0.0265232864767313, 0.051271021366119385, -0.07359956949949265, 0.007749865762889385, -0.052031464874744415, -0.01887608878314495, -0.04738244414329529, -0.08796540647745132, -0.008718663826584816, 0.05257579684257507, 0.06036514416337013, 0.0010009461548179388, -0.03773690387606621, -0.07604289054870605, 0.052478112280368805, 0.02133285440504551, -0.059670526534318924, 0.03364051505923271, -0.004089890513569117, 0.009181871078908443, -0.007040691561996937, 0.17719288170337677, 0.0726088285446167, -0.059029728174209595, 0.02095937356352806, -0.018133919686079025, -0.180853933095932, -0.1183556541800499, 0.03760925307869911, 0.04812311381101608, -0.14389383792877197, 0.258751779794693, 0.006156286224722862, -9.379545666383475e-33, 0.13888640701770782, -0.027663907036185265, 0.05093676969408989, -0.020776493474841118, 0.008024037815630436, 0.002198878675699234, 0.07749757170677185, -0.03501114994287491, 0.05910361930727959, 0.007762892637401819, 0.01757723279297352, 0.04989581182599068, 0.024516232311725616, -0.06349239498376846, -0.07502736896276474, 0.0317688025534153, 0.09381692111492157, -0.07730355113744736, -0.08659788221120834, -0.000962468795478344, 0.007075030822306871, 0.12694840133190155, -0.11698463559150696, -0.022230302914977074, 0.028665058314800262, -0.06273971498012543, 0.07006402313709259, 0.08468634635210037, -0.061324991285800934, -0.05581054836511612, 0.08793894946575165, 0.13188041746616364, -0.23062019050121307, -0.04287813976407051, -0.1193241998553276, -0.05031658709049225, 0.09467697143554688, -0.13748440146446228, 0.0879116803407669, -0.1235126480460167, 0.13967695832252502, -0.013110483065247536, -0.08172833919525146, 0.0331684872508049, 0.02883964218199253, 0.02975376695394516, 0.054534588009119034, -0.08992224931716919, 0.11318778246641159, -0.10159385204315186, -0.04067640006542206, -0.029719466343522072, 0.008544256910681725, 0.05011478438973427, -0.0056269546039402485, -0.00640612468123436, 0.06351933628320694, 0.032550159841775894, -0.07882805913686752, 0.021136661991477013, -0.039781734347343445, 0.06199241429567337, 0.1046496257185936, 0.002912916010245681, 0.023694371804594994, 0.11883006244897842, 0.18424144387245178, 0.06104281172156334, 0.020838778465986252, -0.07360053807497025, 0.005913431290537119, -0.09241197258234024, 0.0005530240596272051, -0.022222347557544708, 0.011483752168715, 0.1174362376332283, 0.033805470913648605, -0.0962294265627861, -0.09729419648647308, -0.05215893313288689, 0.10090893507003784, -0.17344984412193298, -0.07042954117059708, 0.06221144273877144, 0.06910376250743866, 0.08271260559558868, 0.09391754120588303, -0.04022015631198883, -0.014406043104827404, 0.1104704737663269, -0.1364079713821411, -0.14909334480762482, -0.11431003361940384, 0.10392670333385468, 0.08996711671352386, -1.0068086453429714e-07, 0.1907515525817871, -0.0295062568038702, -0.07187430560588837, -0.08473953604698181, -0.05191710591316223, -0.016178272664546967, -0.08457300812005997, 0.1027332991361618, -0.06914535164833069, 0.13443805277347565, 0.05633953958749771, 0.1520722210407257, -0.06720734387636185, 0.0956798642873764, 0.059330083429813385, 0.07311731576919556, -0.059833064675331116, 0.05525487661361694, -0.045227568596601486, -0.06676416099071503, -0.13271142542362213, -0.03301302343606949, 0.053334277123212814, -0.08253146708011627, 0.08670692890882492, -0.13961541652679443, 0.056049883365631104, -0.07660168409347534, -0.052662186324596405, -0.11152780055999756, -0.1205950602889061, 0.058913055807352066, 0.08839716762304306, -0.00816461630165577, -0.05073568597435951, -0.10373777151107788, 0.007724883500486612, -0.015047652646899223, 0.033330392092466354, 0.05247337743639946, -0.06383383274078369, -0.07431524246931076, -0.04292593151330948, -0.020948581397533417, 0.06549299508333206, 0.09069041907787323, -0.07567096501588821, 0.1198507770895958, -0.07160037755966187, -0.07062892615795135, -0.03699266165494919, 0.07708045840263367, 0.057715367525815964, 0.03102191723883152, -0.10531598329544067, 0.2530514597892761, -0.050869669765233994, -0.050198040902614594, 0.06996429711580276, 0.001194132142700255, 0.15489062666893005, -0.02762247435748577, 0.006097263190895319, 0.01325919944792986], "changes": {"1wk": 5.68181956725673, "1mo": 9.659088523057854}}, {"text": "New Strong Sell Stocks for November 27th Zacks Equity Research Wed, Nov 27, 2024, 12:42 PM 1 min read In This Article: AKBA -5.36% ABG -2.46% Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Akebia Therapeutics, Inc. AKBA is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 26.3% downward over the last 60 days. Asbury Automotive Group, Inc. ABG is an automotive retailer. The Zacks Consensus Estimate for its current year earnings has been revised 6.7% downward over the last 60 days. Clean Harbors, Inc. CLH is an environmental and industrial services provider. The Zacks Consensus Estimate for its current year earnings has been revised 5.8% downward over the last 60 days. View the entire Zacks Rank #5 List. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Asbury Automotive Group, Inc. (ABG) : Free Stock Analysis Report Clean Harbors, Inc. (CLH) : Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AKBA", "date": "2024-11-27T12:42:00", "sentiment": {"score": -0.442095460370183, "confidence": 0.4674866795539856, "probabilities": {"positive": 0.025391219183802605, "negative": 0.4674866795539856, "neutral": 0.5071221590042114}}, "embedding": [-0.1557859182357788, -0.16703656315803528, 0.0457938015460968, 0.11817172914743423, -0.02892392873764038, -0.06016632542014122, -0.00802755169570446, 0.046998754143714905, -0.047700151801109314, 0.009396914392709732, -0.0754319503903389, 0.1343781054019928, -0.04097197577357292, -0.06451025605201721, 0.005776687059551477, 0.09887418150901794, 0.154981330037117, -0.08860450237989426, -0.205625519156456, -0.03048851154744625, -0.13565082848072052, -0.011140787042677402, 0.08809053897857666, -0.02081490308046341, 0.022614022716879845, 0.048717133700847626, -0.0024885041639208794, 0.02398782968521118, -0.036316320300102234, -0.1622372567653656, -0.16533702611923218, -0.026368489488959312, 0.16976122558116913, -0.09888292104005814, 0.009603437036275864, 0.07375968992710114, -0.07806544005870819, 0.04093748703598976, 0.18262054026126862, -0.03866227716207504, 0.08134525269269943, 0.014751375652849674, -0.05481869354844093, -0.1275891810655594, -0.21800166368484497, -0.1384507566690445, -0.011138045229017735, -0.052924659103155136, 0.15560349822044373, 0.042440976947546005, -0.16838844120502472, -0.13624273240566254, 0.06711988896131516, -0.059063300490379333, -0.1090695708990097, -0.08781198412179947, -0.28821486234664917, -0.10757261514663696, 0.01683093048632145, -0.061874669045209885, 0.23251552879810333, 0.012354166246950626, 0.06298979371786118, 0.0439462810754776, 0.0805869847536087, 0.015151258558034897, 0.048973627388477325, 0.05349988862872124, -0.031201543286442757, -0.03440845012664795, 0.04899735748767853, -0.1029086634516716, -0.048668961971998215, 0.05953267961740494, -0.08256521075963974, 0.05812966078519821, 0.08961395919322968, 0.008488074876368046, 0.1473061740398407, -0.13932853937149048, 0.05443535000085831, -0.06327758729457855, 0.03282185643911362, -0.08007912337779999, -0.023611729964613914, -0.01122283935546875, 0.081016905605793, 0.0750773698091507, 0.013159078545868397, 0.012075921520590782, 0.19677399098873138, 0.05515775457024574, 0.10631275177001953, -0.09863322973251343, -0.047250907868146896, 0.03938353806734085, -0.07367543131113052, 0.07836491614580154, -0.11278490722179413, 0.08148782700300217, 0.055518243461847305, 0.30686503648757935, -0.06147659569978714, -0.065166175365448, -0.006434299983084202, -0.13398079574108124, 0.015178317204117775, 0.03362777829170227, -0.011653369292616844, 0.08575157821178436, -0.0346643291413784, 0.1135634109377861, -0.06915897130966187, 0.04046032205224037, -0.09165742993354797, 0.10070029646158218, -0.04255492985248566, 0.04757002368569374, 0.18704883754253387, 0.12010975927114487, 0.08174833655357361, 0.0956786572933197, -0.01711633987724781, -0.0025345361791551113, 0.031358782202005386, 0.1782902330160141, -0.12704616785049438, 1.066211138951835e-32, -0.09930071979761124, 0.15257816016674042, 0.07848026603460312, -0.044900521636009216, -0.0834524855017662, -0.0794718861579895, -0.08040137588977814, -0.052520085126161575, -0.11084998399019241, -0.007415578234940767, -0.14912495017051697, 0.13513697683811188, -0.05492357537150383, -0.05082568898797035, 0.034312013536691666, -0.11285346001386642, -0.08263320475816727, -0.03722124919295311, 0.06738924980163574, -0.07492140680551529, 0.02783953957259655, 0.01977832429111004, -0.07962285727262497, 0.014563806354999542, 0.048734068870544434, -0.05395922809839249, 0.06725985556840897, 0.0988636240363121, -0.13774271309375763, 0.10578848421573639, -0.009166532196104527, 0.06703037768602371, -0.16657307744026184, -0.006850712466984987, -0.16285811364650726, -0.06456008553504944, -0.2127765417098999, -0.013113283552229404, 0.03874879330396652, -0.1022709459066391, -0.08994793891906738, 0.07510527968406677, -0.23022539913654327, -0.006776866503059864, 0.025058023631572723, 0.02359415777027607, -0.17648008465766907, 0.043105341494083405, 0.12709619104862213, 0.10825841873884201, -0.15088756382465363, 0.017101222649216652, -0.04798240214586258, 0.04507657513022423, -0.08602675795555115, 0.01987079530954361, 0.0677240788936615, -0.0996219590306282, 0.04308704286813736, 0.08722586184740067, 0.12035217881202698, 0.18327920138835907, 0.003911840729415417, -0.09273626655340195, -0.18177418410778046, 0.11203436553478241, 0.016528408974409103, 0.11141300946474075, -0.11156406253576279, 0.07781078666448593, 0.14844933152198792, 0.04742554947733879, 0.10295417904853821, -0.023291321471333504, 0.004518143832683563, -0.09174619615077972, 0.08707735687494278, 0.010660278610885143, 0.05864064022898674, 0.09849090129137039, 0.13425575196743011, 0.03733430057764053, 0.06964178383350372, 0.07942608743906021, 0.012153358198702335, -0.033330295234918594, 0.028021564707159996, 0.018311595544219017, -0.05604752153158188, -0.021854281425476074, 0.06826996058225632, 0.025056300684809685, -0.081843800842762, 0.09973485767841339, -0.12124604731798172, -1.0747604358969685e-32, 0.1630561202764511, -0.019181357696652412, 0.05391528829932213, -0.033773522824048996, -0.1187651976943016, -0.055160656571388245, 0.11347328871488571, 0.1361713409423828, 0.019642235711216927, 0.01043786108493805, 0.13814972341060638, 0.18033620715141296, -0.04471033811569214, 0.03160946071147919, 0.07781536132097244, -0.05068131536245346, 0.08777903765439987, -0.11610626429319382, -0.008293856866657734, -0.15039804577827454, 0.08128099888563156, 0.13191883265972137, -0.12504708766937256, 0.29781609773635864, -0.025774391368031502, 0.005147726275026798, -0.03693421557545662, 0.05402728542685509, -0.02379019558429718, 0.06162222847342491, 0.03782343491911888, 0.10103482007980347, -0.059102486819028854, 0.18808549642562866, -0.15812240540981293, -0.08473176509141922, 0.06889862567186356, -0.1227298378944397, -0.09685445576906204, -0.10691534727811813, 0.1202506348490715, 0.10975318402051926, -0.10470239073038101, 0.020367536693811417, 0.03971460834145546, 0.07962799817323685, 0.09154603630304337, -0.059847328811883926, 0.12714539468288422, -0.0629233866930008, -0.0019897855818271637, 0.015897754579782486, -0.04601827636361122, 0.10433314740657806, -0.12641511857509613, 0.15255814790725708, 0.07373126596212387, -0.041503168642520905, -0.24809949100017548, 0.005243806634098291, -0.03408144786953926, 0.20184209942817688, 0.04227865859866142, 0.048447079956531525, -0.07395869493484497, 0.033695586025714874, 0.05867840722203255, 0.004085111897438765, -0.034515295177698135, -0.1685262769460678, -0.058747369796037674, -0.12288793921470642, 0.013307584449648857, -0.15308339893817902, -0.062464382499456406, 0.2494167685508728, -0.027944473549723625, -0.12475553900003433, -0.14596375823020935, -6.0455346101662144e-05, 0.059674810618162155, 0.014268669299781322, -0.07105100899934769, 0.16523899137973785, -0.020099392160773277, 0.028071204200387, -0.023669332265853882, -0.07610659301280975, 0.04717821255326271, 0.0911785364151001, -0.06759636104106903, -0.20028851926326752, -0.1537846326828003, 0.20880375802516937, 0.053457774221897125, -9.964974623244416e-08, 0.1058276891708374, -0.10007072240114212, 0.07005800306797028, 0.004959713201969862, 0.06869551539421082, -0.035379085689783096, -0.09529878944158554, 0.04325341060757637, 0.03580130636692047, 0.09861879795789719, -0.0019512699218466878, -0.012045004405081272, -0.271429181098938, 0.10466375201940536, -0.15719956159591675, 0.016104258596897125, -0.07977861166000366, 0.06427834928035736, 0.029026513919234276, -0.2193373143672943, -0.0672420784831047, 0.05816914141178131, 0.22523336112499237, 0.05985405296087265, 0.09806165844202042, -0.008918101899325848, -0.13304440677165985, -0.05042882636189461, 0.060689400881528854, -0.031069675460457802, -0.01768212951719761, 0.017529750242829323, 0.12849049270153046, 0.05532173439860344, 0.0339384526014328, -0.03709296137094498, 0.008551400154829025, 0.010927349328994751, -0.08388784527778625, 0.10073770582675934, -0.03633509576320648, -0.06190953403711319, -0.1269434243440628, -0.04231128469109535, 0.05194571241736412, 0.015500077977776527, -0.11770732700824738, 0.015580588951706886, 0.07960012555122375, -0.19060496985912323, 0.17173856496810913, -0.10644105076789856, 0.0659925639629364, 0.13634724915027618, -0.029687104746699333, 0.14963586628437042, -0.23625241219997406, -0.08620918542146683, -0.009329901076853275, 0.016673272475600243, 0.09811995923519135, -0.2233772724866867, -0.006797651294618845, 0.0994260385632515], "changes": {"1wk": -0.9708728874782327, "1mo": -6.31067955546739}}, {"text": "Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 editorial-team@simplywallst.com (Simply Wall St) Sat, Nov 9, 2024, 4:33 PM 3 min read In This Article: AKBA -5.36% Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters. It definitely looks like a negative result overall with revenues falling 16% short of analyst estimates at US$37m. Statutory losses were US$0.10 per share, 58% bigger than what the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Akebia Therapeutics after the latest results. See our latest analysis for Akebia Therapeutics NasdaqCM:AKBA Earnings and Revenue Growth November 9th 2024 After the latest results, the three analysts covering Akebia Therapeutics are now predicting revenues of US$179.1m in 2025. If met, this would reflect a satisfactory 5.4% improvement in revenue compared to the last 12 months. Losses are expected to increase substantially, hitting US$0.26 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$177.5m and losses of US$0.33 per share in 2025. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a considerable decrease in losses per share in particular. These new estimates led to the consensus price target rising 10% to US$5.50, with lower forecast losses suggesting things could be looking up for Akebia Therapeutics. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Akebia Therapeutics analyst has a price target of US$7.50 per share, while the most pessimistic values it at US$4.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. For example, we noticed that Akebia Therapeutics' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 4.3% growth to the end of 2025 on an annualised basis. That is well above its historical decline of 12% a year over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 21% per year. So although Akebia Therapeutics' revenue growth is expected to improve, it is still expected to grow slower than the industry. Story Continues The Bottom Line The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving. With that in mind, we wouldn't be too quick to come to a conclusion on Akebia Therapeutics. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Akebia Therapeutics analysts - going out to 2026, and you can see them free on our platform here. You should always think about risks though. Case in point, we've spotted 3 warning signs for Akebia Therapeutics you should be aware of, and 2 of them can't be ignored. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AKBA", "date": "2024-11-09T16:33:34", "sentiment": {"score": -0.32632413506507874, "confidence": 0.6450554132461548, "probabilities": {"positive": 0.31873127818107605, "negative": 0.6450554132461548, "neutral": 0.036213308572769165}}, "embedding": [-0.04893818870186806, -0.057936765253543854, -0.04970914125442505, 0.1250123381614685, -0.04903598874807358, 0.017727814614772797, 0.04174376651644707, 0.11807334423065186, 0.16152873635292053, 0.11245058476924896, -0.23498964309692383, 0.07156425714492798, 0.003085421398282051, -0.05501813441514969, -0.04912383854389191, 0.03357178717851639, 0.05144621059298515, -0.040359023958444595, -0.1775171458721161, 0.07881049811840057, -0.1194586306810379, 0.006147795356810093, 0.0009795930236577988, -0.02822905220091343, 0.08403269946575165, 0.025050651282072067, -0.0412367582321167, -0.11660830676555634, -0.1861792504787445, -0.1077035665512085, -0.02448713779449463, 0.027217606082558632, 0.09155672043561935, -0.1377669870853424, -0.06304044276475906, -0.036386214196681976, -0.2027987241744995, 0.11506737768650055, 0.09915672987699509, 0.012363254092633724, 0.08686381578445435, 0.014617347158491611, -0.11771467328071594, 0.022055769339203835, -0.14220210909843445, -0.17446163296699524, -0.03093598783016205, 0.0017101513221859932, 0.04231240972876549, 0.16095659136772156, -0.2861764430999756, -0.17490342259407043, 0.02363245189189911, -0.05382295697927475, -0.06361585855484009, -0.03724229708313942, -0.14995843172073364, -0.053802818059921265, 0.05902519077062607, 0.07019704580307007, 0.018148411065340042, 0.09571738541126251, 0.06956804543733597, 0.031435128301382065, 0.21654048562049866, -0.045758023858070374, 0.09289900213479996, 0.016329998150467873, -0.07054628431797028, 0.0319938063621521, 0.09224818646907806, -0.051822252571582794, 0.006199827417731285, -0.04483712092041969, -0.05193508043885231, 0.07186923921108246, 0.12723271548748016, 0.15423917770385742, 0.1908630132675171, -0.08197063952684402, 0.02878175675868988, -0.024808039888739586, -0.09643372148275375, -0.11740795522928238, -0.016254577785730362, -0.01737971045076847, 0.169123113155365, 0.025324000045657158, 0.10913556069135666, 0.024831917136907578, 0.18343225121498108, -0.05845702812075615, 0.06617271900177002, -0.0069387201219797134, 0.08964433521032333, 0.017401136457920074, -0.15106211602687836, -0.09048910439014435, -0.0007459386251866817, 0.08785124123096466, 0.10012104362249374, 0.17590297758579254, -0.04205884784460068, -0.12103292346000671, -0.04699605703353882, -0.2082960158586502, 0.03355298936367035, -0.06478113681077957, -0.0629415363073349, 0.130289226770401, -0.08060821890830994, 0.023132845759391785, -0.061774127185344696, -0.029936933889985085, 0.03321519121527672, -0.007966783829033375, 0.02952631562948227, 0.015189124271273613, 0.0612792931497097, 0.07362568378448486, -0.00034956971649080515, 0.0879330039024353, 0.09186092764139175, -0.0007533358875662088, 0.023113785311579704, 0.07456010580062866, -0.22023126482963562, 1.2808727173961023e-32, 0.023981399834156036, -0.06496124714612961, 0.0913456529378891, -0.14462926983833313, -0.08651888370513916, -0.03668653592467308, -0.0969485193490982, -0.05756642669439316, -0.025228219106793404, -0.10019123554229736, -0.21762090921401978, 0.12074388563632965, -0.004578979220241308, 0.03667570650577545, 0.024666929617524147, -0.036880798637866974, 0.014480656944215298, 0.057303160429000854, 0.02224399521946907, 0.05334486812353134, -0.01973128318786621, 0.02794242464005947, -0.04017044976353645, 0.055787019431591034, -0.057097092270851135, 0.08657678961753845, -0.03631161153316498, 0.035629548132419586, -0.1254015415906906, 0.039823658764362335, -0.10281354188919067, -0.009954327717423439, -0.036070819944143295, -0.09014333039522171, -0.10333634912967682, -0.07659436762332916, -0.07845889031887054, 0.04384402558207512, 0.060348931699991226, 0.04782528802752495, -0.1183709129691124, 0.08226387947797775, -0.09598525613546371, -0.06232529878616333, 0.040950387716293335, 0.005707721225917339, -0.08644653111696243, -0.006406430155038834, -0.07822230458259583, -0.07004698365926743, -0.06788080185651779, 0.011098578572273254, 0.05091804265975952, 0.03559195622801781, -0.013308029621839523, 0.034577712416648865, -0.03783044591546059, -0.061146143823862076, 0.11980767548084259, 0.047529540956020355, 0.06118054315447807, 0.1726151704788208, 0.07423701882362366, -0.05297033488750458, -0.23451843857765198, 0.19913062453269958, 0.05734753981232643, 0.08836758136749268, -0.06755097955465317, 0.06296651065349579, 0.04458111524581909, 0.03033081814646721, 0.10040226578712463, 0.012573140673339367, 0.06668516993522644, -0.043169330805540085, 0.02926269918680191, -0.021363958716392517, 0.07270130515098572, 0.050840262323617935, 0.06513231247663498, 0.004593019373714924, 0.05037781968712807, 0.033884547650814056, 0.057215362787246704, -0.060911282896995544, 0.03870251402258873, 0.026046499609947205, -0.14533370733261108, -0.006575897801667452, 0.07250003516674042, 0.015660934150218964, -0.1282108873128891, 0.17872315645217896, 0.058040834963321686, -1.337642776258683e-32, -0.004202935844659805, 0.05744219571352005, -0.01606031134724617, -0.0567653626203537, -0.07815659791231155, -0.062187276780605316, 0.08966267853975296, 0.05898815765976906, -0.0320417620241642, 0.02207639068365097, 0.04049032926559448, -0.012344269081950188, -0.06765272468328476, 0.06931436061859131, -0.05512581765651703, -0.07297700643539429, 0.19118732213974, -0.11921930313110352, -0.011547185480594635, -0.1474895179271698, 0.0018842002609744668, 0.19950371980667114, -0.1468995213508606, 0.08683833479881287, 0.013859208673238754, 0.012357460334897041, 0.10221904516220093, 0.10498902201652527, -0.13101524114608765, -0.09155131876468658, 0.007828759029507637, -0.02054387331008911, -0.2245349884033203, 0.04837026447057724, -0.06110094487667084, -0.01316208578646183, 0.07563319057226181, -0.18270663917064667, -0.08334732055664062, -0.11308548599481583, 0.15413692593574524, 0.10018955171108246, 0.00795760378241539, 0.02451145648956299, 0.08994345366954803, -0.0014815215254202485, 0.07460501790046692, -0.003175352932885289, 0.17534348368644714, -0.026607461273670197, 0.042335525155067444, -0.04129460081458092, -0.04151034727692604, 0.07320322096347809, -0.10829583555459976, 0.0008040787652134895, 0.012189529836177826, -0.03321396932005882, -0.05004022270441055, 0.053731974214315414, -0.09377402812242508, 0.03822566941380501, 0.12235359847545624, -0.05493185669183731, -0.04454021528363228, 0.08579746633768082, 0.1433161050081253, 0.04971916973590851, 0.016895629465579987, -0.11549177765846252, 0.024170126765966415, -0.09596310555934906, -0.02313069812953472, -0.014400924555957317, 0.017030395567417145, 0.2805846333503723, -0.012724116444587708, -0.0831947773694992, 0.04275369644165039, -0.008574272505939007, 0.08456829935312271, -0.07560667395591736, -0.011275098659098148, -0.00030457228422164917, -0.005314928945153952, 0.041842907667160034, 0.07840768992900848, -0.05878033488988876, -0.06264202296733856, 0.10614815354347229, -0.10593239217996597, -0.21202632784843445, -0.14652109146118164, 0.06680141389369965, 0.08052688837051392, -1.012425485669155e-07, 0.06878330558538437, -0.04858410358428955, 0.052371229976415634, 0.03488817811012268, 0.09368060529232025, -0.05157065764069557, -0.07168278098106384, 0.010768410749733448, 0.06206545978784561, 0.12780998647212982, 0.1223432719707489, 0.028327401727437973, -0.19943293929100037, 0.1482100486755371, -0.0769004300236702, 0.10329916328191757, -0.07857996225357056, 0.02096579596400261, -0.0027331337332725525, -0.18809491395950317, -0.07104557007551193, 0.050641581416130066, 0.07146166265010834, -0.11970234662294388, 0.15932098031044006, -0.14980021119117737, -0.09464162588119507, 0.049282416701316833, -0.07443171739578247, 0.0008777529001235962, -0.01684482954442501, 0.022320689633488655, 0.039644524455070496, 0.0031803178135305643, -0.044574446976184845, -0.07291436940431595, 0.11189854145050049, 0.05223646014928818, 0.04015619307756424, 0.10690867155790329, -0.10172615945339203, -0.0674360990524292, -0.002697473391890526, -0.043333716690540314, -0.044964589178562164, -0.033017948269844055, -0.09923640638589859, 0.04401003569364548, -0.007304475177079439, -0.24642810225486755, 0.10010366886854172, -0.034750841557979584, 0.04718053340911865, 0.09573403745889664, 0.09505408257246017, 0.0260199885815382, -0.15746763348579407, -0.047795090824365616, -0.14772750437259674, 0.047108255326747894, 0.05501579865813255, -0.24653184413909912, -0.023533890023827553, 0.10318959504365921], "changes": {"1wk": -10.050253604283867, "1mo": 3.015072487035241}}, {"text": "U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo\u00ae (vadadustat) for CKD Patients on Dialysis PR Newswire Tue, Dec 3, 2024, 3:00 PM 9 min read In This Article: AKBA -5.36% Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care CAMBRIDGE, Mass. , Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics\u00ae, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that in late November U.S. Renal Care (USRC) enrolled the first patient in its Vafseo\u00ae (vadadustat)\u00a0Outcomes In-Center Experience (VOICE) collaborative trial. Akebia announced the collaborative trial initiation in September 2024 . Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.) \"We look forward to begin treating CKD anemia patients on dialysis with Vafseo ahead of its anticipated market launch in January 2025 ,\" said Steven K. Burke , M.D., Chief Medical Officer of Akebia. \"The study has been designed to evaluate Vafseo safety and efficacy when dosed three times a week to align with patients' current dialysis schedule as well as to explore additional potential patient benefits. We congratulate Dr. Geoff Block and his team at USRC on quickly consenting patients for the study and thank him for his commitment to patients impacted by kidney disease.\" Vafseo was approved by the U.S. Food and Drug Administration in March 2024 for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is approved for once-daily oral administration and is expected to be available in the U.S. in January 2025 . The VOICE trial intends to enroll approximately 2,200 patients who will be randomized to oral Vafseo 300 mg tablets administered three times per week or standard-of-care erythropoiesis-stimulating agents. The trial will end approximately 18 months after the last patient is randomized. The primary endpoint is non-inferiority for all-cause mortality and the secondary endpoint will test superiority of Vafseo to reduce all-cause hospitalization. More information about the VOICE trial can be found here . About U.S. Renal Care U.S. Renal Care partners with nephrologists across 32 states in the U.S. to care for more than 36,000 people living with kidney disease. Since 2000, U.S. Renal Care has been a leader in clinical quality, innovation, and operational excellence \u2013 delivering the best experience and outcomes for our patients. For more information, visit USRenalCare.com. About Akebia Therapeutics Akebia Therapeutics, Inc.\u00a0is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release. Story Continues About Vafseo\u00ae (vadadustat) tablets Vafseo\u00ae (vadadustat) tablets is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin, increasing hemoglobin and red blood cell production to manage anemia. Vafseo is approved for use in 37 countries. INDICATION VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being. VAFSEO is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. In patients with anemia due to\u00a0CKD not on dialysis. IMPORTANT SAFETY INFORMATION about VAFSEO (vadadustat) tablets WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS. VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE). Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels. No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks. Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions. CONTRAINDICATIONS Known hypersensitivity to VAFSEO or any of its components Uncontrolled hypertension WARNINGS AND PRECAUTIONS Increased Risk of Death, Myocardial Infarction (MI), Stroke, Venous\u00a0Thromboembolism, and Thrombosis of Vascular Access A rise in hemoglobin (Hb) levels greater than 1 g/dL over 2 weeks can increase these risks. Avoid in patients with a history of MI, cerebrovascular event, or acute coronary syndrome within the 3 months prior to starting VAFSEO. Targeting a Hb level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events. Use the lowest effective dose to reduce the need for red blood cell (RBC) transfusions. Adhere to dosing and Hb monitoring recommendations to avoid excessive erythropoiesis. Hepatotoxicity Hepatocellular injury attributed to VAFSEO was reported in less than 1% of patients, including one severe case with jaundice. Elevated serum ALT, AST, and bilirubin levels were observed in 1.8%, 1.8%, and 0.3% of CKD patients treated with VAFSEO, respectively. Measure ALT, AST, and bilirubin before treatment and monthly for the first 6 months, then as clinically indicated. Discontinue VAFSEO if ALT or AST is persistently elevated or accompanied by elevated bilirubin. Not recommended in patients with cirrhosis or active, acute liver disease. Hypertension Worsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. Serious worsening of hypertension was reported in 2.7% of VAFSEO and 3% of darbepoetin alfa patients. Cases of hypertensive crisis, including hypertensive encephalopathy and seizures, have also been reported in patients receiving VAFSEO. Monitor blood pressure. Adjust anti-hypertensive therapy as needed. Seizures Seizures occurred in 1.6% of VAFSEO and 1.6% of darbepoetin alfa patients. Monitor for new-onset seizures, premonitory symptoms, or change in seizure frequency. Gastrointestinal (GI) Erosion Gastric or esophageal erosions occurred in 6.4% of VAFSEO and 5.3% of darbepoetin alfa patients. Serious GI erosions, including GI bleeding and the need for RBC transfusions, were reported in 3.4% of VAFSEO and 3.3% of darbepoetin alfa patients. Consider this risk in patients at increased risk of GI erosion. Advise patients about signs of erosions and GI bleeding and urge them to seek prompt medical care if present. Serious Adverse Reactions in Patients with Anemia Due to\u00a0CKD and Not on Dialysis The safety of VAFSEO has not been established for the treatment of anemia due to CKD in adults not on dialysis and its use is not recommended in this setting. In large clinical trials in adults with anemia of CKD who were not on dialysis, an increased risk of mortality, stroke, MI, serious acute kidney injury, serious hepatic injury, and serious GI erosions was observed in patients treated with VAFSEO compared to darbepoetin alfa. Malignancy VAFSEO has not been studied and is not recommended in patients with active malignancies. Malignancies were observed in 2.2% of VAFSEO and 3.0% of darbepoetin alfa patients. No evidence of increased carcinogenicity was observed in animal studies. ADVERSE REACTIONS The most common adverse reactions (occurring at \u2265 10%) were hypertension and diarrhea. DRUG INTERACTIONS Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron. Non-iron-containing phosphate binders : Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders. BCRP substrates : Monitor for signs of substrate adverse reactions and consider dose reduction. Statins : Monitor for statin-related adverse reactions. Limit the daily dose of simvastatin to 20 mg and rosuvastatin to 5 mg. USE IN SPECIFIC POPULATIONS Pregnancy: May cause fetal harm. Lactation: Breastfeeding not recommended until two days after the final dose. Hepatic Impairment : Not recommended in patients with cirrhosis or active, acute liver disease. Please note that this information is not comprehensive. Please click here for the Full Prescribing Information, including BOXED WARNING and Medication Guide. Forward-Looking Statements Statements in this press release regarding\u00a0Akebia Therapeutics, Inc.'s\u00a0(\"Akebia's\") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the\u00a0U.S.\u00a0Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to, statements regarding:\u00a0 Akebia's expectations regarding the VOICE trial, including expectations as to the potential benefits and risks of Vafseo when dosed three times a week in dialysis patients, and Akebia's expectations as to the timing of the market availability of Vafseo in the\u00a0U.S. The terms \"intend,\" \"believe,\" \"plan,\" \"goal,\" \"potential,\" \"anticipate, \"estimate,\" \"expect,\" \"future,\" \"will,\" \"continue,\" derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to, risks associated with: whether Vafseo will be commercially available when expected; manufacturing, supply chain and quality matters and any recalls, write-downs, impairments or other related consequences or potential consequences; the results of preclinical and clinical research; the potential therapeutic benefits, safety profile, and effectiveness of Vafseo; the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to Vafseo; the competitive landscape for Vafseo; the ability of Akebia to attract and retain qualified personnel; decisions made by health authorities, such as the FDA, with respect to regulatory filings; the direct or indirect impact of the COVID-19 pandemic on the markets and communities in which Akebia and its partners, collaborators, vendors and customers operate; and early termination of any of Akebia's collaborations. Other risks and uncertainties include those identified under the heading \"Risk Factors\" in Akebia's Quarterly Report on Form 10-Q for the quarter ended\u00a0September 30, 2024, and other filings that Akebia may make with the\u00a0U.S. Securities and Exchange Commission\u00a0in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and, except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release. Akebia Therapeutics\u00ae and Vafseo\u00ae are registered trademarks of Akebia Therapeutics, Inc. Akebia Therapeutics Contact Mercedes Carrasco mcarrasco@akebia.com Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/us-renal-care-enrolled-first-patients-in-the-voice-collaborative-clinical-trial-of-vafseo-vadadustat-for-ckd-patients-on-dialysis-302320302.html SOURCE Akebia Therapeutics, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AKBA", "date": "2024-12-03T15:00:00", "sentiment": {"score": 0.22311429493129253, "confidence": 0.23410537838935852, "probabilities": {"positive": 0.23410537838935852, "negative": 0.010991083458065987, "neutral": 0.7549034953117371}}, "embedding": [-0.16416718065738678, -0.1378105878829956, -0.004176812246441841, -0.1311902403831482, -0.25959160923957825, -0.01817547157406807, -0.07961967587471008, 0.16892479360103607, 0.1846136450767517, 0.0025945398956537247, -0.15341666340827942, 0.11152829229831696, -0.16379842162132263, -0.06260114908218384, 0.013821748085319996, -0.13859082758426666, 0.22813951969146729, 0.022571895271539688, -0.15541765093803406, 0.0840589851140976, 0.072130486369133, 0.010902324691414833, 0.02127664163708687, -0.14590324461460114, 0.11195595562458038, 0.0030518712010234594, -0.18306604027748108, -0.11576724052429199, -0.05580126866698265, -0.06143493205308914, 0.08560416102409363, 0.03371519595384598, 0.029974080622196198, -0.05607663840055466, -0.012056393548846245, 0.11130701750516891, -0.2670174241065979, 0.05991719290614128, -0.26481688022613525, -0.11461925506591797, 0.007341119460761547, -0.12205718457698822, -0.12890669703483582, 0.03280007839202881, -0.08635373413562775, -0.11672128736972809, -0.12478668987751007, -0.006604520604014397, 0.08498169481754303, 0.22416678071022034, -0.20151934027671814, -0.17259342968463898, 0.11842192709445953, 0.08127159625291824, -0.15553823113441467, -0.07382498681545258, -0.044252730906009674, -0.014200801029801369, -0.015165204182267189, -0.09079790115356445, -0.1581232249736786, 0.02434059977531433, 0.02975163795053959, -0.0467611625790596, 0.1107902005314827, 0.09722475707530975, 0.1341221034526825, -0.19932007789611816, 0.08908658474683762, -0.2012716829776764, 0.05039595440030098, 0.03221464902162552, 0.06823466718196869, 0.1709001064300537, -0.017974015325307846, 0.13621021807193756, 0.029179682955145836, 0.0010886553209275007, 0.2240542769432068, -0.15650689601898193, 0.15413884818553925, 0.16318009793758392, 0.05611284077167511, 0.01240137591958046, 0.007275932934135199, 0.025908539071679115, -0.044356197118759155, 0.0859852284193039, -0.002879455452784896, -0.0514855831861496, 0.20695646107196808, 0.14278556406497955, 0.12639681994915009, -0.030469998717308044, -0.008261844515800476, -0.017079157754778862, -0.16242314875125885, -0.05747242271900177, 0.012901954352855682, 0.035946086049079895, -0.05567365139722824, 0.0774768739938736, -0.06474045664072037, -0.08866698294878006, 0.0062566231936216354, -0.06617804616689682, -0.027272069826722145, -0.07795651257038116, -0.005004446487873793, 0.07651277631521225, -0.05594305694103241, 0.0016995624173432589, 0.09138612449169159, 0.014461669139564037, 0.0131756030023098, 0.08470016717910767, -0.00728045916184783, -0.024244988337159157, 0.19119024276733398, -0.01647251471877098, 0.005825864151120186, -0.037034906446933746, -0.0013584531843662262, -0.10858094692230225, 0.05559121072292328, 0.1565943956375122, 0.020214945077896118, 7.513513036642389e-33, 0.016942234709858894, -0.044665995985269547, 0.14708277583122253, -0.0028698276728391647, -0.03734768182039261, 0.03524160385131836, -0.03904183954000473, -0.006086645647883415, -0.025708522647619247, -0.2097042351961136, -0.14304588735103607, -0.04502139613032341, -0.02075900137424469, 0.14225898683071136, -0.08532597124576569, -0.05684232711791992, -0.0566931776702404, 0.014752237126231194, 0.11156372725963593, 0.10497797280550003, 0.1853751540184021, -0.02582760900259018, 0.06641101837158203, 0.11353658139705658, -0.07278427481651306, -0.07500627636909485, -0.07011619210243225, 0.08813266456127167, -0.026525985449552536, 0.054908715188503265, -0.1256505399942398, 0.02525606006383896, -0.022731639444828033, -0.23014266788959503, -0.2279205322265625, -0.05385855585336685, -0.07350032031536102, -0.05800770968198776, -0.1218637079000473, -0.010629554279148579, -0.1262013465166092, 0.08604408800601959, -0.11372356116771698, -0.08221349120140076, 0.1294047236442566, -0.10406281054019928, -0.16230949759483337, -0.037862442433834076, -0.060511521995067596, 0.02116464264690876, -0.13585087656974792, -0.0568738654255867, 0.03718855604529381, 0.0179546307772398, 0.07097022235393524, 0.029571395367383957, -0.03536565229296684, -0.06833689659833908, 0.057563237845897675, 0.10745483636856079, 0.1307741105556488, 0.13527730107307434, 0.0772867500782013, 0.10535553097724915, -0.1450985074043274, 0.029995955526828766, -0.007188728079199791, -0.08960165828466415, -0.041536133736371994, -0.06680655479431152, -0.07740724086761475, 0.030795985832810402, 0.03156023845076561, -0.029100660234689713, -0.08855991065502167, -0.16320937871932983, 0.08760859072208405, 0.0160243920981884, 0.003054168773815036, 0.013628482818603516, 0.07140706479549408, -0.01574769616127014, -0.09327265620231628, 0.21711638569831848, 0.09649064391851425, -0.0541706420481205, 0.03431163355708122, -0.019849980250000954, -0.20167270302772522, -0.19050276279449463, 0.09950307756662369, 0.04649163782596588, -0.07071449607610703, 0.2370428740978241, 0.05833272635936737, -1.051783268226636e-32, 0.1154593750834465, 0.06601119041442871, 0.03298664838075638, 0.03764422982931137, 0.10140971839427948, 0.0652124285697937, 0.12561140954494476, -0.06358015537261963, 0.080423504114151, 0.012682970613241196, 0.056827813386917114, 0.06853513419628143, 0.08139953017234802, -0.023362454026937485, -0.10379831492900848, 0.04644457995891571, 0.013091649860143661, -0.1699991226196289, -0.03524042293429375, 0.06273479759693146, 0.029753267765045166, 0.09248188138008118, -0.06843048334121704, 0.10384352505207062, 0.03210938349366188, -0.146018385887146, 0.09181788563728333, 0.08296041935682297, -0.06325235217809677, -0.10223877429962158, 0.0704297423362732, 0.07881675660610199, -0.22332987189292908, -0.03481209650635719, -0.021175436675548553, -0.06061495095491409, 0.18896812200546265, -0.1275164932012558, 0.034451067447662354, -0.0763373002409935, 0.12634605169296265, 0.014292553067207336, -0.10182911902666092, -0.04943874478340149, -0.03109203279018402, 0.013148622587323189, 0.0655229464173317, -0.08914630860090256, 0.052192553877830505, -0.172077476978302, 0.038213081657886505, 0.08282440900802612, 0.06971774995326996, 0.15299880504608154, -0.0001650797203183174, -0.03149477019906044, 0.1162678673863411, -0.007871042937040329, -0.13834014534950256, 0.1201600432395935, -0.065578393638134, 0.021911974996328354, 0.13650161027908325, -0.08092311769723892, 0.08172611892223358, 0.10124629735946655, 0.20634132623672485, 0.0822795182466507, 0.08256857097148895, -0.049267929047346115, -0.08400159329175949, -0.12916357815265656, 0.018448946997523308, -0.0610409751534462, 0.055578235536813736, 0.07037591189146042, 0.08277066797018051, -0.09272792935371399, -0.07907991856336594, -0.11861173063516617, 0.014560315757989883, -0.17324790358543396, -0.1019911915063858, 0.034954555332660675, 0.02717917039990425, 0.09570275992155075, 0.13896328210830688, -0.11681308597326279, 0.06274949014186859, 0.2209889441728592, -0.13337403535842896, -0.14950542151927948, -0.05923484265804291, 0.06494737416505814, 0.0984935313463211, -1.0136777461866586e-07, 0.14523884654045105, 0.01933452859520912, 0.04303663969039917, -0.035908035933971405, -0.009447479620575905, -0.12644201517105103, -0.011088022030889988, 0.053668998181819916, -0.09172537177801132, 0.10389681905508041, 0.102810338139534, 0.1710025817155838, -0.05197659879922867, 0.10025554895401001, 0.11698386073112488, 0.10536175966262817, 0.005909420549869537, 0.15889206528663635, -0.054767023772001266, 0.025865988805890083, -0.12332077324390411, -0.06056585907936096, -0.039571795612573624, -0.1119353175163269, 0.07452158629894257, -0.06740601360797882, 0.09297311305999756, -0.057781435549259186, -0.011237564496695995, -0.02768075279891491, -0.09386177361011505, 0.028868302702903748, 0.07558291405439377, -0.05128275603055954, -0.12189541757106781, -0.10347011685371399, -0.03375404700636864, 0.01132766529917717, 0.03890927881002426, 0.021769274026155472, -0.013208940625190735, -0.02101990394294262, -0.0341411717236042, -0.030558453872799873, 0.11394938826560974, 0.10754532366991043, -0.12089761346578598, 0.05310213565826416, -0.06706468015909195, -0.05179490149021149, -0.055192671716213226, 0.09690337628126144, 0.013795108534395695, 0.024545416235923767, 0.023334834724664688, 0.21515542268753052, -0.051918141543865204, -0.08912952244281769, 0.15023356676101685, -0.020802710205316544, 0.18368259072303772, -0.05117393285036087, -0.0652027502655983, -0.06548623740673065], "changes": {"1wk": 0.0, "1mo": -6.862744525137968}}]